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Abstract 
 
Robust sex differences in daily and circadian activity rhythms, as well as the 
manifestation of circadian disruption-associated pathologies, have been reported in 
numerous species, including humans and laboratory models.  These differences are 
mediated, at least in part, by sexually dichotomous estrogenic signaling throughout life.  
However, the mechanism(s) underlying the impact of estrogens on the formation and 
expression of circadian activity outputs remains poorly characterized.  A more 
comprehensive understanding of both the full effect(s) of estrogenic signaling on 
circadian rhythms throughout life and the precise method by which these effects are 
exacted will expand our understanding of the intersection of endocrinology and 
chronobiology, provide greater insight regarding disease pathogenesis, and provide novel 
targets for the development of efficacious therapies aimed at circadian disruption 
prevention and alleviation.   
Accordingly, I have three primary goals for this thesis. First, I will fully 
characterize the effects of acutely circulating estradiol on the expression of daily and 
circadian wheel running rhythms in female mice.  Simultaneously, I will further elucidate 
the estrogen receptor-dependent mechanism(s) underlying these functional effects 
(Chapter 2).  Second,  I will examine the impact of developmental estradiol on adult daily 
and circadian activity rhythms during a neonatal critical period associated with 
maturation of the suprachiasmatic nucleus (SCN), a hypothalamic structure regarded as 
the ‘master oscillator’ (Chapter 3). Finally, because the adult timekeeping system is 
dependent upon transcriptional regulation in the SCN, I will determine the impact of 
estradiol on gene expression within the SCN (Chapter 4).   
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In the work presented here, I show that acutely circulating estradiol increases total 
wheel activity, consolidates this activity to the dark phase, and enhances wheel running 
amplitude through mechanism(s) dependent upon estrogen receptor subtype 1 (ESR1) in 
female mice.  Additionally, estradiol more uniformly distributes wheel running activity 
across the dark phase compared to control treatment, delays the time of peak activity 
(acrophase), reduces the phase angle of activity onset, and dampens the behavioral 
response elicited by a pulse of light administered in the early subjective night, though 
these effects are mediated by estrogen receptor subtype 2 (ESR2).  Activation of either 
ESR1 or ESR2 shortens the length of the endogenous day.  I further discovered that 
developmental exposure to estradiol plays a distinct role in organizing the adult time 
keeping system.  Lack of estradiol during a neonatal period associated with SCN 
maturation increases total wheel running in adult male mice, an effect rescued by 
exogenous estradiol administration during this critical period.  Treatment with estradiol 
during this same period in female mice reduces the quantity and amplitude of adult wheel 
running, advances activity acrophase, and condenses the majority of activity completed 
during the dark phase to the early subjective night.  Exogenous estrogen given during 
SCN organization shortens the length of the active phase in adult male mice, and robustly 
effects responsiveness to light at varying times of day, though in a highly sex-dependent 
manner. Finally, activational estradiol strongly alters the transcriptional makeup within 
the SCN of female mice, primarily through message downregulation.  Enriched 
molecular pathways in which estradiol decreased transcript expression of critical players 
include circadian rhythms, mitogen activated peptide kinase (MAPK) signaling, 
neurotrophin signaling, and long-term potentiation, suggesting that estradiol may be 
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dampening plasticity within the SCN.  These effects may contribute to the behavioral 
impact of estradiol outlined in Chapter 2.  Together, these data significantly increase our 
understanding of the activational and organizational effects of estradiol on daily and 
circadian wheel running activity rhythms, and provide foundational targets for future 
work further elucidating the causative mechanism(s) underlying their expression. 	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Introduction to Circadian Rhythms 
Understanding Circadian Rhythms 
From single cellular organisms to plants to complex mammalian species, the 
homeostatic temporal patterning of daily biological and behavioral processes is well 
documented (Roenneberg and Merrow, 2002).  These highly conserved daily, or 
circadian, rhythms exist at subcellular, cellular, tissue, and organismal levels (O’Neill et 
al., 2013).  Distinct biological oscillations, both in accordance with and in spite of 
environmental variation, are critical for survival.  Indeed, disruption of daily rhythms has 
been associated with numerous pathologies in humans and mammalian models, including 
sleep disorders, cardiovascular complications, metabolic disease, immune system 
impairment, cancer, psychiatric disease, and drug/alcohol addiction (Turek et al., 2001; 
Wirz-Justice, 2003; Rosenwasser, 2010; Takahashi et al., 2008; Reddy and O’Neil, 2010; 
Karatsoreos, 2012; Bailey and Silver, 2013). 
The term ‘circadian’ refers to a rhythm that oscillates around an approximately 24 
hr day, the duration of which is controlled, at least in part, by a transcriptional-
translational feedback loop (TTFL) expressed within the suprachiasmatic nucleus (SCN) 
(O’Neill et al., 2013).  Accordingly, this bilateral hypothalamic structure is regarded as 
the ‘master oscillator’.  Simplistically, the TTFL that mediates the length of the innate 
day, or period, begins with the nuclear transcription of both Clock and Bone Muscle Aryl 
Hydrocarbon Receptor Nuclear Translocator-Like (Bmal1) message (Figure 1.1).  These 
transcripts are translated in the endoplasmic reticulum, and their protein products 
dimerize before re-entering the nucleus.  Within the nucleus, CLOCK-BMAL1 binds to 
the genome through interaction with its E-box response element, promoting the 
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transcription of Period (Per) and Cryptochrome (Cry).  Following protein synthesis, PER 
and CRY also dimerize prior to feeding back and directly inhibiting the transcription of 
Clock and Bmal1 (Zhang and Kay, 2010).  A continually evolving list of directly and 
peripherally associated regulatory players, both at the genomic and proteomic levels, 
precisely fine tune this ‘simple’ TTFL, thereby mediating the duration of the observed 
period of slightly less than 24 hr in rodents and slightly greater than 24 hr in humans (Jud 
et al., 2005; Refinetti, 2010; Zhang and Kay, 2010; O’Neill et al., 2013). 
In addition to setting the innate oscillatory period, the 10-20,000 neurons within 
the SCN also integrate highly diverse neurochemical inputs, adapting downstream 
circadian outputs.  Light is the strongest exogenous input to influence the functions of the 
SCN (Figure 1.2) (Bailey and Silver 2013).  Light activates non-image forming 
intrinsically photosensitive retinal ganglion cells (Leak et al., 1999; Berson et al., 2002; 
Brown and Piggins, 2007), which then transduce photic cues onto the SCN via 
glutamatergic signaling along the retinohypothalamic tract (RHT).  Additional retinal 
photic input projects onto the SCN via the geniculohypothalamic tract (GHT), which 
begins in the intergeniculate leaflet (IGL) (Morin et al., 2013).   
The heterogeneous neuronal population within the SCN acts in a coordinated 
fashion through neural and diffusible signaling to exert control over the clock-controlled 
activities expressed by its efferent targets (Figure 1.2).  These regulated activities are 
numerous and include gene expression, proteomic regulation, hormone release, feeding, 
and activity.  The focus of the remainder of this document is rodent wheel running 
behavior.  Accordingly, unless stated otherwise, all of the explanation of circadian 
rhythms that follow will be in reference to this behavior.  Feedback mechanisms prevent 
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light- or dark-induced potentiation of clock-controlled outputs.  For example, nocturnal 
rodents such as mice, rats, and hamsters complete more wheel revolutions in the dark 
compared to the light.  If the absence of light and associated downstream signaling onto 
the SCN contributes to this cyclic rhythm, one could reason that it would be 
disadvantageous to become increasingly more active as the dark phase progressed.  
Indeed, multiple negative feedback loops exist that balance outputs, inputs, and the SCN 
itself (Figure 1.2) (Bailey and Silver, 2013). 
  Importantly, the SCN is both required and sufficient for the expression of 
biological and behavioral circadian rhythms.  Circadian oscillations in body temperature, 
endocrine function, and behavior are lost following surgical SCN ablation in rodents 
(Welsh et al., 2010), but are fully restored to donor rhythmicity when fetal SCN grafts are 
implanted into lesioned hosts (Ralph et al., 1990; King et al., 2003).  Interestingly, only 
15-20% of the neurons in the SCN graft need to be functional for the functional 
restoration of rhythmicity.  Oscillations in transcript levels of the 10-20% of genes whose 
expression is innately rhythmic (Reddy et al., 2006; Deery et al., 2009; Doherty and Kay, 
2010; Reddy, 2013) continue for several days after dissociated cell culture preparation 
(Welsh et al., 2004; Yoo et al., 2004), suggesting that individual SCN cells themselves 
play a large role in the expression of oscillations.  Additionally, these individual SCN 
neurons are capable of acting in concert to coordinate peripheral clocks, a phenomenon 
lost following SCN ablation (Welsh et al., 2010; Tahara et al., 2012).  These neurons also 
couple to synchronize circadian outputs, demonstrating that even though circadian 
rhythms are inherent to each cell, the overarching network control created by overlapping 
negative and positive feedback loops is greater than the sum of its parts. 
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Methodology for understanding daily and circadian activity patterns 
To assess daily and circadian wheel running behaviors, rodents are singly housed 
with free access to a running wheel.  Wheel rotations are recorded and plotted over time.  
The resultant actogram is shown in Figure 1.3A.  The white and black bars across the top 
indicate whether the lights were on (white) or off (black), while each line is 
representative of a different day.  Frequently, actograms are drawn to show 2 consecutive 
days side by side, a format known as double-plotting (Jud et al., 2005).  This style 
permits simple visualization of rhythmic trends.  Total wheel rotations are binned and 
plotted chronologically over time; the height of the bar for a given bin is indicative of the 
magnitude of wheel running completed within that time.  In addition to denoting the total 
quantity of wheel running activity exerted by a given animal, these data are useful for 
determining if the animal’s activity pattern is synchronized, or entrained, to the light:dark 
(LD) environment in which it is housed.  A nocturnal animal entrained to LD will 
become active around the time of lights off and will cease to be active when the lights 
turn back on as long as the artificial length of day is set within entrainable limits.  
Further, these data can be used to assess when the animal becomes active relative to 
lights off, a measure known as the phase angle of activity onset (Jud et al., 2005; Bailey 
and Silver, 2013). 
Time is arbitrary within an LD environment.  To account for this, Zeitgeber 
(Zeitgeber = “time giver”) time (ZT) is employed to standardize environmental cues to 
the clock.  Within a 12:12 LD environment, ZT0 denotes the time at which the lights turn 
on, while ZT12 indicates lights off.  Rodents, for example the C57Bl/6 mice used in all of 
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the subsequent chapters, when housed in constant conditions with no entraining cues free 
run and	  exhibit	  a	  day	  length	  or	  innate free running period (Tau; τ) that is slightly less 
than 24 hr (23.7 ± 0.1 hr) (Zheng et al., 2001; Jud et al., 2005).  Accordingly, when they 
are placed in constant darkness (DD) and all Zeitgebers are removed, activity patterns 
emerge that adhere to this endogenous rhythm (Figure 1.3A).  The length of the active 
phase (α) is also an innate property.  Notably, τ and α are disrupted by SCN ablation 
(Welsh et al., 2010), further reinforcing the hypothesis that circadian behavioral rhythms 
are governed by the SCN.  Period is determined by measuring either peak to peak or 
trough to trough activity.   Because there is typically only one definitive wheel running 
activity peak per subjective day, but potentially very many equal troughs, the peak to 
peak definition is most frequently employed (Figure 1.3B).  Activity onset to activity 
onset is also a highly stable method for determining τ.  Both τ and α should be quantified 
over several days after animals have acclimated to constant lighting conditions to avoid 
both adjustment effects and single day anomalies. 
Within a given circadian rhythm there exists an activity peak and activity trough.  
The Raw Amplitude describes the magnitude of the rhythm and is defined as the peak 
minus the trough (Figure 1.3B).  To account the differences in the mean level of activity 
(mesor) between individuals, the Adjusted Amplitude of the activity rhythm is defined as 
the peak minus the mesor (Refinetti, 2010).  Irrelevant of its magnitude, the time at which 
the peak bin of wheel running activity occurs is known as the Acrophase (Figure 1.3B).  
Acrophase in nocturnal rodents typically occurs in the early subjective night, while 
humans and diurnal animals exhibit peak activity during the light phase (Duffy et al., 
2011).  Similar to τ and α, Amplitude and Acrophase should be calculated from several 
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consecutive days of behavioral output to most accurately describe an animal’s daily and 
circadian activity patterns. 
 To determine the ability of an animal to adjust its timing, or phase, of activity in 
response to a change in exogenous photic cue, a phase response experimental design is 
used.  The results of such a paradigm are shown in Figure 1.3C.  Animals entrained to an 
LD environment are permitted to free run in total darkness for at least 24 hr but not long 
enough to permit recapitulation of the endogenous rhythm.  They are then subjected to a 
pulse of light, which is indicated by a yellow star, at varying times of day.  Following the 
light pulse, animals continue to free run in DD for at least 8 continuous days.  The 
difference between activity onset in LD prior to light pulse administration and activity 
onset in DD following the pulse is used to determine the magnitude of the phase shift.  
Activity onset is defined as the first bin of continuous wheel running whose magnitude is 
equal to or greater than at least 10% of the peak activity bin.  At least 3 days of 
continuous LD data should be used to determine pre-pulse activity onset, while a 
regression line fit through the activity onset of at least 5 days of post-pulse DD data 
should be used.  The first day after the animal is subjected to the light pulse should be 
disregarded to account for after effects (Jud et al., 2005). 
A pulse administered at a time when the animal is accustomed to being in the 
light, for example ZT4 or ZT11, elicits little to no response (Figure 1.3C) (Bailey and 
Silver, 2013).  Periods of time normally associated with lights on that do not elicit a 
phase shift in activity are known as dead zones (Jud et al., 2005).  Animals receiving a 
pulse in the early subjective night (ZT16) respond by delaying the start of activity onset 
the next day, a phenomenon known as phase delay.  Conversely, a maximal phase 
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advance is elicited by a light pulse in the late subjective night (ZT22) (Jud et al., 2005; 
Bailey and Silver, 2013).  The ability to phase shift in response to environment stimuli is 
adaptive and demonstrates behavioral plasticity within the SCN, its inputs, and efferent 
targets.  Similarly, introduction of an exogenous drug or behavioral intervention may 
alter the magnitude or timing of phase shifts compared to those observed in control 
animals.  These effects may be due to treatment effect(s) upstream, downstream, or at the 
level of the SCN.  
 The paradigm used to measure phase shifts in response to alterations in 
environmental photic input described above is known as an Aschoff type II protocol.  
Alternatively, an Aschoff type I design dictates that circadian time (CT) be calculated for 
each individual mouse based on their respective duration of free running rhythm.  This is 
done by first defining the time of activity onset exhibited by a nocturnal animal that has 
been acclimated to DD free running conditions as CT12.  This time is then added to the 
animal’s measured τ, and 24 hr is subtracted, yielding the formula: CT12(subsequent day) = 
(CT12(measured day) + τ – 24 hr).  Additionally, the length of each circadian hour for a given 
animal is defined as τ/24 hr (reviewed in Jud et al., 2005).  Accordingly, the magnitude of 
each unit time can vary from animal to animal because rather than applying time as a 
unified constraint for all experimental animals, it is standardized to each subject’s free 
running rhythm.  In order to use an Aschoff type I design to measure photic-induced 
phase shifts, two important variables should be considered.  First, in order for this design 
to elicit consistent and reproducible data, it is critical that all subjects exhibit highly 
stable circadian activity patterns under constant light conditions.  Second, all mice are 
subjected to the same stimuli uniformly, but the time at which the light pulse was 
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delivered is retroactively computed for each animal, resulting in pulse administration at 
varying CTs across subjects.  Accordingly, all work describing phase shifting of activity 
onset in response to light for the remainder of this document was done using the Aschoff 
type II paradigm. 
 
Sex differences with daily and circadian activity rhythms: a case for estrogen 
There are robust sex differences in daily and circadian activity rhythms 
(Karatsoreos, 2012; Mong et al., 2011; Bailey and Silver, 2013).  Several of these 
differences were discovered through the exogenous manipulation of gonadal or ovarian 
hormone levels or availability, suggesting that sex hormones play a critical role in the 
regulation of circadian behaviors.  Despite an increasingly vast body of work outlining 
the link between sex differences, sex hormones, circadian behavior, and the diseases 
associated with their disruption, less than 20% of published research at the intersection of 
chronobiology and endocrinology focuses specifically on females and/or ovarian 
signaling (Kuljis et al., 2013).  Notably, the incidence of circadian disruption is increased 
during periods characterized by either acute or chronic shifts in estrogen signaling, 
including the perinatal period, pregnancy, menopause, and the reproductive cycle (Morin 
and Cummings, 1982; Baker et al., 2007; Mahoney, 2010; Shechter and Boivin, 2010), 
suggesting that estradiol plays a role in modifying clock controlled outputs (Figure 1.4).   
This hypothesis has been repeatedly supported by experimental data.  Maximum 
daily wheel running activity in intact female rats and hamsters is observed during 
proestrous when serum estradiol levels are at their peak (Wollnik and Turek, 1988), while 
removal of circulating estrogens via ovariectomy (OVX) reduces total wheel running 
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activity in female mice, rats, and degus (Albers, 1981; Labyak and Lee, 1995; Ogawa et 
al., 2003; Brockman et al., 2011).  This effect is rescued by exogenous estradiol 
replacement (Rodier, 1971; Gentry and Wade, 1976).  In female rats and hamsters, 
estradiol shortens τ (Morin et al., 1977a; Zucker et al., 1980; Albers, 1981) and advances 
the phase angle of activity onset (Morin et al., 1977b; Albers, 1981).  Female OVX 
hamsters have greater phase angle variability compared to intact or estradiol-treated 
counterparts (Morin and Cumming, 1982).  Additionally, asynchronous wheel running 
rhythms and splitting, a phenomenon observed in hamsters when constant LL leads to the 
emergence of two distinct daily activity rhythms, are reduced in OVX females following 
estradiol replacement (Morin and Cumming, 1982).  Further, the quantity of wheel 
running activity completed by female nocturnal rodents during the light phase is 
increased following OVX, but made more nocturnal by subsequent estradiol replacement 
(Ogawa et al., 2003; Brockman et al., 2011; Blattner and Mahoney, 2012).  Together, 
these data suggest that estrogens modulate both the magnitude and timing of wheel 
running activity, as well as strengthen entrainment to LD transitions (Gorman and Lee, 
2002).  
Estrogens not only contribute to the expression of the circadian activity rhythms 
described above, but also to the ability to adjust to unanticipated environmental changes.  
For example, intact female degus subjected to a 6 hr phase shift recover more slowly than 
their male counterparts (Goel and Lee, 1995), suggesting that this sex difference can be 
attributed, at least partially, to female sex hormones.  Further, intact female estrogen 
receptor knock-out mice (αERKO), which lack estrogen subtype receptor 1 (ESR1; 
formerly ERα), but not estrogen subtype receptor 2 (ESR2; formerly ERβ) (Dupont et al., 
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2000), exhibit a truncated phase delay when pulsed with light in the early subjective 
night, but a more robust phase advance when the pulse is administered in the late 
subjective night compared to intact WT female mice (Blattner and Mahoney, 2013).  
Together, these data provide evidence that modified or impaired estrogen signaling alters 
the adaptive response to photic stimuli.   
Our understanding of the effects of estradiol on daily and circadian activity 
rhythms, though insufficiently characterized, is more complete than our knowledge of the 
mechanism(s) by which these effects are enacted.  As is possible with any exogenous 
stimuli capable of altering daily and circadian activity rhythms, estradiol may be acting 
by modulating afferent and efferent SCN projections.  It may also act directly on the SCN 
itself (Figure 1.4).  In the mature mouse brain, estrogen receptors are expressed in all 
three of the major inputs onto the SCN, including the RHT, the IGL, as well as the 5-HT-
associated medial (MR) and dorsal raphe (DR) nuclei (Figure 1.5A).  Input carried on the 
RHT and GHT conveys photic retinal information.  GHT-mediated input is associated 
with arousal and processing the length of day (Mintz et al., 2001; Webb et al., 2008; 
reviewed in Bailey and Silver, 2013), while the DR/MR pathway transmits activity and 
exercise information (van Esseveldt et al., 2000).  The presence of circulating ligand 
often influences the activational expression of receptors (Vida et al., 2008), suggesting 
that sex differences in hormonal milieu may, in part, mediate sex differences in receptor 
expression within these pathways.  Importantly, the type(s) of estrogen receptors 
expressed in each of these locations, which are likely to influence when and how 
estradiol effects SCN inputs, have not been fully characterized.   
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The SCN itself also expresses estrogen receptors (Figure 1.5A,B) and does so in a 
sex-dependent manner.  The SCN can be divided into an outer shell and inner core.  Shell 
neurons frequently express arginine vasopressin (AVP) and exhibit much greater 
oscillatory amplitude and stronger rhythm than core neurons.  Vasoactive intestinal 
polypeptide (VIP) and gastrin releasing peptide (GRP) are primarily expressed in select 
core neurons.  Further, retinal projections directly input onto core, but not shell neurons 
(Figure 1.5A) (reviewed in Bailey and Silver, 2013).  Importantly, the patterning of ESR1 
and ESR2 is distinct with respect to SCN location (Figure 1.5A,B).  ESR2 is more 
robustly expressed in the SCN than ESR1 and is isolated to non-AVP expressing shell 
neurons, of which ~38% were ESR2 positive (Vida et al., 2008).  While only a small 
number of neurons express ESR1 (male mice: ~3%; female mice: ~4.5%), it is found 
almost exclusively in non-VIP and non-GRP core neurons (Vida et al., 2008).  Like mice, 
human women have higher basal levels of SCN ESR1 expression (Kruijver et al., 2002).  
Interestingly, no differences in ESR2 levels in the human SCN have been detected across 
the sexes (Kruijver et al., 2002), while female mice have substantially higher ESR2 levels 
than males (Vida et al., 2008).  Further complicating the patterning of these receptors 
within the substructural regions of the SCN is the fact that exogenous administration of 
estradiol reduces ESR2, but not ESR1, expression in both males and females (Vida et al., 
2008).  Consequently, innate sex differences in estrogen receptor expression within the 
SCN and circulating estradiol contribute to acute receptor patterning, though the degree 
to which each contributes remains poorly characterized. 
Finally, estradiol may regulate SCN efferents.  Modulation of estrogenic signaling 
at this level may directly alter clock-controlled activity outputs downstream of, and 
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therefore, in spite of the SCN.  Additionally, the ability of these regions (Figure 1.4,1.5B) 
to feedback onto the SCN raises the possibility that ligand binding at any of these targets 
may indirectly modulate the SCN, consequently impacting daily and circadian activity 
rhythms.  The potential estrogenic networks between the SCN and its efferents are 
complex and extensive.  The SCN directly projects onto 15 distinct brain regions (Morin, 
2013), all of which--with the exception of the sub paraventricular zone (sPVZ) and the 
ventrolateral preoptic area (VLPO)--express at least one type of estrogen receptor (Figure 
1.5B) (Bailey and Silver, 2013).  Further, the SCN receives coincident feedback from at 
least 35 brain regions.  Multisynaptic connections involving these regions yields an 
estimated 85 distinct SCN innervation patterns (Morin, 2013). It is unlikely that a single 
pathway is responsible for all of the effects exerted by estradiol on daily and circadian 
activity rhythms.  While speculative and not the direct focus of this thesis, it is far more 
likely that a number of distinct and overlapping mechanisms together are responsible for 
these robust effects. 
At the molecular level, estrogens canonically activate their cognate receptors, 
principally estrogen subtype receptor 1 (ESR1; formerly ERα) and estrogen receptor 
subtype 2 (ESR2; formerly ERβ) in the central nervous system, which then act as 
transcription factors (Figure 1.6).  Specifically, cytosolic ligand-bound intracellular 
estrogen receptors decouple from heat shock proteins, dimerize, and bind a variety of co-
activators and repressors prior to entering the nucleus and binding to their respective 
DNA response elements (King and Greene, 1984; DeMarzo et al., 1991; O’Malley and 
Tsai, 1992; O’Malley, 2006; Rosenfeld et al., 2006).  However, this homodimer-mediated 
nuclear binding pathway is not the whole story.  The discovery of additional estrogenic 
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mechanisms has expanded our understanding of how estradiol regulates gene 
transcription and neuronal excitability.  For example, estrogen-bound receptors that 
complex with other transcription factors are capable of binding to DNA sites outside of 
their respective response elements (Uht et al., 1997).  Additionally, estrogen-induced 
recruitment of co-activators and co-repressors alters DNA methylation, acetylation, and 
phosphorylation, supporting an epigenetic role for estradiol (O’Malley, 2006; Rosenfeld 
et al., 2006).  Beyond nuclear translocation, there is strong evidence that both membrane-
bound and cytosolic estrogen receptors initiate protease and kinase-dependent 
intracellular signaling cascades that drive genomic plasticity (Figure 1.6) (Gu et al., 1996; 
Zhou et al., 1996; Watters et al., 1997; Bi et al., 2001; Abraham et al., 2004; Zadran et 
al., 2009).  Exogenous estradiol also enhances neuronal excitability within the SCN 
(Fatehi and Fatehi-Hassanabad, 2008), possibly through the bidirectional potentiation of 
NMDA receptors (Tanaka and Sokabe, 2013) and regulation of presynaptic GABA 
release (Gillespie et al., 1996; Novak and Albers, 2004), thereby mediating neuronal 
excitability.  Importantly, it is possible that activated ESR1 and ESR2 act through one or 
many of these mentioned pathways. 
 
 
Activational vs Organizational Estrogenic Signaling 
Importantly, when estradiol influences the formation and expression of daily and 
circadian rhythms is as important as where and how in the brain it acts.  Estradiol can act 
through both organizational and activational mechanisms (Arnold, 2009), and indeed, 
there is evidence that both contribute to circadian activity rhythms (Lee et al., 2004; 
Hagenauer et al., 2011; Brockman et al., 2011; Blattner and Mahoney, 2012; Kujlis et al., 
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2013).  However, the attribution of different circadian activity variables to organizational 
and/or activational regulation, as well as defining the underlying molecular mechanism(s) 
is incomplete.   
During early development, sex determination is primarily driven by the testis 
determining factor-encoding sry gene on the Y chromosome (Figure 1.7).  Subsequent 
sex differentiation is then mediated by developmental temporal patterning of androgens, 
estrogens, and progestins, which program adult hormone responsiveness.  Early postnatal 
development is characterized by a brief surge in androgen production by the testis in 
males (Konkle and McCarthy, 2011).  In the brain, and especially within the 
hypothalamus, androgens are rapidly converted to estradiol by the aromatase cytochrome 
p450 enzyme (George and Ojeda, 1982; Roselli and Resko, 1993; Konkle and McCarthy, 
2011).  This results in high circulating brain estradiol levels in neonatal males, and 
substantially lower levels in neonatal females (Figure 1.7).  Peri- and neonatal exposure 
to estrogens and/or androgens exert a masculinizing effect on the brain (Phoenix et al., 
1959; Arnold, 2009), while the lack of these hormones or the sequestration of estrogens 
by alpha-fetoprotein (Uriel at al., 1976) results in a feminized default.  This early life 
exposure organizes neural circuits and their respective molecular milieu, adjusting 
hormone responsiveness in the adult.  Following puberty, the high circulating estradiol 
and progesterone levels characteristic of adult females and high testosterone levels 
associated with males activationally influence sex specific circadian phenotypes.  For 
example, female mice exhibit greater quantities of daily wheel running activity than their 
male counterparts (Figure 1.7) (Blattner and Mahoney, 2012). 
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There is experimental evidence supporting a role for organizational estrogenic 
control over daily and circadian activity rhythms.  Female rodents masculinized in the 
neonatal period fail to shorten τ when administered estradiol as adults (Zucker et al., 
1980; Albers, 1981).  Further, sex differences characteristic of certain circadian variables 
cannot be not altered by the manipulation of adult sex hormone levels.  For example, the 
inability of female hamsters to entrain to varying LD schedules--a characteristic not 
observed in males--is not affected by modulation of circulating gonadal hormones.  
However, the limits of entrainment in these animals is made more plastic if hormonal 
manipulation is completed during sexual development (Davis et al., 1983).  Aromatase 
knock-out (ArKO) mice lack the aromatase cytochrome p450 enzyme, and are, therefore, 
unable to convert testosterone to estradiol (Honda et al., 1998).   ArKO females, 
irrespective of OVX status, exhibit less wheel running activity, but a longer τ than OVX 
WT females (Brockman et al., 2011), demonstrating innate differences in circadian 
activity resulting from absent estrogen signaling throughout the organizational period.  
Together, these data strongly suggest that ovarian hormones exert organizational actions 
to shape circadian behaviors.   
However, these actions alone cannot explain the profound effects of circulating 
estradiol on daily activity rhythms.  The discovery that total wheel running exhibited by 
OVX WT females treated with estradiol complete significantly more total wheel 
revolutions than estradiol-treated αERKO OVX females (Ogawa et al., 2003) suggests 
the predominance of activational, rather than organizational, estradiol-associated control 
over daily activity patterns.  However, the use of global knock-out mice and potential for 
perinatal and/or neonatal effects of absent estrogen signaling further muddle the 
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understanding of what parameters are and are not mediated by developmental and/or 
acute regulation.  
 
Conclusions 
The critical importance of circadian outputs is well documented.  Sex differences 
in activity biorhythms, the increased prevalence of shifts in biorhythmic activity during 
life events characterized by altered estrogenic signaling, and the enrichment of estrogen 
receptors in circadian-dependent brain regions strongly support a role for estradiol in the 
expression and formation of daily and circadian activity rhythms.  However, the robust 
influence exerted over these biorhythms by estrogenic signaling is poorly understood, 
including the effects of developmental versus acutely circulating estradiol.   
In the work that follows, I will expand our current understanding of the 
relationship between estradiol and circadian behavior rhythms by testing my central 
hypothesis that estradiol acts through both organizational and activational mechanisms to 
impact the expression of daily and circadian activity rhythms in mice.  Additionally, the 
influence of acutely circulating estradiol on the expression of gene regulatory networks 
within the SCN will be examined in an effort to correlate estradiol-induced genomic 
regulation with its control over activity biorhythms.  Specifically, in Chapter 2, I will test 
the hypotheses that estradiol exerts control over daily and circadian activity rhythms in 
female mice, and that these effects are mediated, in part, by ESR1 and/or ESR2-
dependent mechanisms.  In Chapter 3, I will explore the developmental role that 
estrogenic signaling plays in the organization of adult biorhythmic activity outputs during 
a critical period associated with SCN maturation using male and female mice.  I will test 
the hypotheses that exogenous	  early	  life	  estradiol	  disrupts	  the	  expression	  of	  daily	  and	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circadian	  activity	  rhythms	  in	  adult	  mice,	  and	  also	  that	  estradiol administration during 
SCN maturation will rescue disrupted rhythms in mice lacking estrogenic signaling at all 
other developmental times.	  	  Finally, in Chapter 4, I will use female mice to test the 
hypothesis that estradiol and light alter the expression of gene regulatory networks in the 
SCN at a time of day when estradiol impedes behavioral plasticity. This novel work 
greatly enhances our understanding of the intersection between circadian rhythms and sex 
hormone signaling, and serves as a platform for numerous future studies aimed at further 
elucidating the mechanisms by which estradiol mediates daily and circadian activity 
rhythms.  
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Figure 1.1. 
 
 
 
Figure 1.1. Simplified Transcription-Translation Feedback Loop (TTFL) within the SCN 
that encodes the length of the innate day. Input such as daily light cues onto the central 
oscillator, the suprachiasmatic nucleus (SCN), drives the transcription of the core clock 
genes clock and bmal1.  The subsequently translated protein products then induce the 
transcription of per and cry, whose protein products then inhibit clock and bmal1 
transcription through a continuous negative feedback loop.  The known players in this 
TTFL are numerous and continually evolving.  This loops takes approximately 24 hr to 
complete a full cycle and is hypothesized to modulate circadian outputs, including 
include gene rhythmicity, metabolism, total activity, and others (modified from Zhang 
and Kay, 2010; Bailey and Silver, 2013).   
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Figure 1.2. 
 
 
Figure 1.2. Circadian feedback paradigm.  Photic input is projected onto the 
suprachiasmatic nucleus (SCN) from the retina.  The SCN responds by transmitting 
neural and diffusible outputs onto its efferents, which then mediate clock controlled 
activity.  Negative feedback from these efferents onto circadian system inputs regulates 
network potentiation (modified from Bailey and Silver, 2013).  
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Figure 1.3. 
 
 
Figure 1.3. Assessment of daily and circadian activity rhythms. (A) Representative 
actogram depicting entrainment, phase angle of activity onset, and magnitude of wheel 
running rhythms over several days in both total darkness (DD) and 12:12 light:dark (LD) 
housing conditions.  Black bars across the top represent lights off during LD, while white 
indicates the lights were on. (B) Circadian parameters assessed based on activity rhythm 
include the mean activity observed per unit time across the 24 hr day (Mesor), the innate 
length of day (Period), the difference between the activity peak and trough (Raw 
Amplitude), the difference between the activity peak and the Mesor (Adjusted 
Amplitude), and the time at which the activity peak occurs (Acrophase).  (C) Shifts in 
phase of activity onset in response to a photic cue can be measured by subjecting animals 
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entrained to LD to a light pulse (indicated by the yellow star) at various times of day and 
measuring the change in phase response.  A pulse administered when the animal is 
accustomed to being in the light (Time: 4hr, 11hr) elicits little response, while a pulse in 
the early subjective night (Time: 14-16hr) will elicit a maximal phase delay.  A phase 
advance is observed when the pulse is administered in the late subjective night (Time: 
22hr) (modified from Bailey and Silver, 2013).  
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Figure 1.4. 
 
 
 
Figure 1.4. Estrogen influenced clock controlled activities.  Estrogens are capable of 
modulating daily and circadian activity rhythms, though our functional understanding of 
the impact of estradiol on these outputs is incomplete.  Further, whether estrogens exert 
these effects by modifying circadian input pathways, the central oscillator itself, output 
pathways from the suprachiasmatic nucleus (SCN), and/or SCN efferent targets has not 
been fully elucidated (modified from Bailey and Silver, 2013).  
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Figure 1.5. 
 
Figure 1.5. Estrogen receptors are expressed upstream, within, and downstream of the 
suprachiasmatic nucleus (SCN). (A) The three main inputs onto the SCN, the 
retinohypothalamic tract (RHT), the geniculohypothalamic tract (GHT) from the 
intergeniculate leaflet (IGL), and the dorsal and medial raphe nuclei (DR and MR) all 
express estrogen receptors. Red indicates that estrogen receptors are expressed in this 
brain region while blue indicates that androgen receptors are expressed.  The specific 
type(s) of receptors present are known for some, but not all, regions shown. (B) The 
SCN itself expresses estrogen receptors.  Similarly, estrogen receptors are expressed by 
most SCN efferent targets, including the anteroventral periventricular zone (AVPV), 
medial preoptic area (mPOA), median preoptic area (MnPO), bed nucleus of the stria 
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terminalis (BNST), lateral septum (LS), amygdala (AMY), paraventricular nucleus of the 
hypothalamus (PVN), anterior paraventricular thalamic nuclei (PVT), habenula (HB), 
IGL, dorsomedial hypothalamus (DMH), ventromedial nucleus of the hypothalamus 
(VMH), retrochiasmatic area (RCh), and the arcuate nucleus (ARC). Hypothalamic 
efferents are indicted by black arrows. Grey arrows indicate extrahypothalamic targets 
(Bailey and Silver, 2013). 
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Figure 1.6. 
 
 
Figure 1.6. Estradiol induces genomic responses in neurons expressing estrogen 
receptors. Ligand-bound estrogen receptors can act directly as nuclear transcription 
factors either by dimerizing and binding their respective estrogen response element 
(ERE) or an alternative TF (Ex: Fos).  Non-nuclear mechanisms that also result in a 
genomic response include initiation of kinase and protease-dependent signaling cascades 
following activation of membrane-bound estrogen receptors, potentiation of estrogen-
sensitive ion channels, and interaction with integral membrane proteins (modified from 
Pinaud and Tremere, 2012). 
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Figure 1.7. 
Figure 1.7. Organizational and activational influence(s) of estradiol on the expression of 
daily and circadian activity rhythms. Sex determination is governed by chromosomal sex 
and, primarily by the SRY gene on the Y chromosome.  Resultant testes development 
leads to high perinatal testosterone levels in males, which is converted to estradiol in the 
brain by aromatase.  Consequently, neonatal males have high brain estradiol levels 
compared to age-matched females.  These early life events organize adult estradiol 
responsiveness.  Following puberty, females have high circulating estradiol and 
progesterone levels, while males have high testosterone.  These circulating hormones 
exert activational effects.  Together, organizational and activational hormone signaling 
drives the mature sex-dependent circadian phenotype.  For example, female mice exhibit 
higher levels of daily wheel running than their male counterparts (modified from Lenz et 
al., 2012).  
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CHAPTER 2: ESR1 and ESR2 differentially regulate daily and circadian activity 
rhythms in female mice 
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Abstract 
Estrogenic signaling shapes and modifies daily and circadian rhythms, the 
disruption of which have been implicated in psychiatric, neurologic, cardiovascular, and 
metabolic disease, among others.  However, the activational mechanisms contributing to 
these effects remain poorly characterized.  To determine the activational impact of 
estrogen on daily behavior patterns and differentiate between the contributions of the 
estrogen receptors ESR1 and ESR2, ovariectomized adult female mice were administered 
estradiol, the ESR1 agonist propylpyrazole triol (PPT), the ESR2 agonist 
diarylpropionitrile (DPN), or cholesterol (CTL).  Animals were singly housed with 
running wheels in a 12:12 Light:Dark cycle or total darkness.  Estradiol increased total 
activity and amplitude, consolidated activity to the dark phase, delayed the time of peak 
activity (acrophase of wheel running), advanced the time of activity onset, and shortened 
the free running period (τ), but did not alter the duration of activity (α).  Importantly, 
activation of ESR1 or ESR2 differentially impacted daily and circadian rhythms.  ESR1 
stimulation increased total wheel running and amplitude, and reduced the proportion of 
activity in the light vs the dark.  Conversely, ESR2 activation modified the distribution of 
activity across the day, delayed acrophase of wheel running, and advanced the time of 
activity onset.  Interestingly, τ was shortened by estradiol or either estrogen receptor 
agonist.  Finally, estradiol-treated animals administered a light pulse in the early 
subjective night, but no other time, had an attenuated response compared to CTL. This 
decreased phase response was mirrored by animals treated with DPN, but not PPT.  To 
conclude, estradiol has strong activational effects on the temporal patterning and 
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expression of daily and circadian behavior, and these effects are due to distinct 
mechanisms elicited by ESR1 and ESR2 activation.   
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Introduction 
Circadian timekeeping systems utilize approximately 24 hr endogenous rhythms 
to adapt and respond to cyclically changing environments.  Disruptions of these rhythms 
are associated with increased incidence of chronic and acute disease, including cancer, 
obesity, metabolic disorder, compromised immunity, cardiovascular disease, sleep 
disorders, and a variety of psychiatric conditions (1-7).  There are sex differences in the 
manifestation of these conditions.  For example, cardiovascular disease and hypertension 
are more prevalent among women subjected to circadian disruptions than in men (8).  
This is perhaps not surprising considering that sex differences in circadian rhythms are 
found across a variety of species (7, 9-12).  Importantly, daily and circadian rhythms are 
modulated in part by shifts in hormone signaling during the perinatal period, pregnancy, 
menopause, and throughout the reproductive cycle (13-16), suggesting ovarian hormones 
such as estradiol play a role in modifying circadian rhythms.   
Indeed, the maximum daily activity in intact female rats and hamsters is observed 
during proestrus, corresponding to peak serum estradiol levels (17).  Removal of 
circulating estrogens via ovariectomy (OVX) reduces total wheel running activity in 
female mice, rats, and degus (18-21), an effect reversed by exogenous estradiol 
replacement (22, 23).  Estradiol shortens the length of the free running period (tau; τ) (18, 
24-26) and advances the onset of wheel running activity in mice, rats, and hamsters (18, 
27).  It also consolidates activity to the dark phase of the LD cycle in mice (20, 21, 28).  
Female OVX hamsters have greater variability in the timing of activity onset compared to 
intact or estradiol-treated counterparts, while the incidence of asynchronous or split 
wheel running rhythms in female OVX hamsters is reduced by estradiol replacement 
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(13).  Further, intact female estrogen receptor knock-out mice (αERKO) in which ESR1 
(formerly ERα), but not ESR2 (formerly ERβ) has been removed (29), exhibit a truncated 
response to a light pulse given in the early subjective night, but a more robust behavioral 
shift when the pulse is administered in the late subjective night compared to intact WT 
female mice (30).  Taken together, these data suggest that estrogens regulate both the 
magnitude and timing of wheel running activity, strengthen entrainment to LD transitions 
(31), and modulate behavioral shifts in response to a photic cue.   
The mechanisms underlying estradiol’s effects on circadian and daily activity 
rhythms, including the roles of ESR1 and ESR2, have yet to be determined.  Ogawa et al. 
(20) utilized αERKO and βERKO mice to demonstrate that ESR1, but not ESR2, 
regulates the estradiol-induced increase in activity.  The difference in total wheel running 
between OVX WT and αERKO, but not βERKO females treated with estradiol (20) 
suggests the predominance of an activational, rather than organizational mechanism that 
is dependent on ESR1.  However, the use of global knockout mice and the potential for 
developmental effects of absent estrogen signaling confound the interpretation of these 
previous studies.  Moreover, total daily activity is the only variable that has been shown 
to be under the control of a specific estrogen receptor. To study the activational effects of 
estrogenic signaling on the expression of daily and circadian activity rhythms, I 
pharmacologically manipulated the activity of ESR1 and/or ESR2 in OVX WT female 
mice.  I show here that receptor activation differentially modulates behavioral 
rhythmicity, suggesting unique roles for ESR1 and ESR2.   
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Methods 
Animals and Housing 
Circadian activity patterns in ESR1 knockout (αERKO; -/-) and wild-type (WT; 
+/+) littermates have been described previously (30).  To ensure this work would be 
comparable to previous studies, αERKO heterozygotes (+/-) on the C57Bl6/J background 
were crossed, and the resulting WT female mice were used. Mice were maintained in 
accordance with the University of Illinois Urbana-Champaign Institutional Animal Care 
and Use Committee guidelines and the NIH guide for the Care and Use of Laboratory 
Animals.  Animals were maintained at a constant temperature (22○C) in 12:12 hr 
light:dark (LD) or constant darkness (DD), and were given food and water ad libitum.  
Animals housed in DD were exposed to a dim red light briefly each day (<5 min) to 
assess animal health but otherwise were not exposed to any light.  
Animals were fed Teklad 2016 rodent diet throughout the study because it 
contains <12 ppm soy estrogen isoflavones, including daidzein and genistein.  These 
levels are subthreshold for eliciting biological activity (per Harlan Laboratories, 2014).  
Animals were group-housed with same sex littermates from weaning (p21) until post 
sexual maturation (p50), at which time they were singly housed in cages (28 cm L x 16 
cm W x 12 cm H) outfitted with a metal running wheel (11 cm diameter) affixed to the 
lid.  During the light phase, the light intensity measured at the top of the cage ranged 
from 220-360 lx (average 290 lx).  
The experimental timeline is shown in Figure 2.1.  Beginning on p50, and 
continuing through two estrous cycles, daily vaginal cytology was performed on each 
animal to confirm cyclicity prior to ovariectomy.  Throughout the study, all vaginal 
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cytology samples were collected at varying times of day to avoid the introduction of a 
confounding time cue.  On p60, running wheels were removed, and mice were 
anesthetized with ketamine/xylazine (100 mg/kg and 10 mg/kg, respectively; i.p.) and 
maintained with isoflurane gas as necessary.  Ovaries were removed through bilateral 
incisions, and the muscle/fascia and overlying skin were closed with surgical silk and 
staples.  Vaginal cytology was examined daily for the next 8-10 days (Figure 2.1) to 
verify that animals were no longer exhibiting signs of cyclicity.  Wheels were returned 
after 5 days of recovery (Figure 2.1). 
 
Drug Pellets and Administration 
To manipulate estrogen receptor activity, I used specific ESR1 and ESR2 
agonists.  The ESR1 agonist 4,4′,4″,-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) 
has a higher relative binding affinity (RBA) for ESR1 over ESR2 and an estimated 1000 
times higher relative potency for ESR1 (32, 33).  Conversely, the RBA and relative 
potent selectivity for ESR2 exhibited by 2,3-bis[4-hydroxyphenyl]-propionitrile (DPN) 
are 70 and 170 fold greater than those observed for ESR1 (34). DPN (rac-DPN (1)) was 
synthesized in the Katzenellenbogen laboratory at the University of Illinois Urbana-
Champaign as described (34, 35).  PPT was purchased from Orbiter Research 
(Champaign, IL).  Administered doses were as follows: 25 µg estradiol (LowE), 50 µg 
estradiol (HighE), 2 mg PPT (LowPPT), 5 mg PPT (HighPPT), 2 mg DPN (LowDPN), 
and 5 mg DPN (HighDPN).  The estradiol concentrations used were selected based on 
those that increased wheel-running activity, uterine weight, and the expression of 
corneated vaginal epithelial cells; these changes occur predominantly through the 
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activation of ESR1 (30, 36-38).  The physiologic pattern of activated ERS1 and ESR2 
throughout the estrous cycle is unknown.  Accordingly, doses of PPT or DPN 100-fold 
greater were chosen to align with previously reported efficacious doses (37, 39-42) and to 
account for the reduced transcriptional activity of these compounds compared to estradiol 
(33, 34).  Specifically, my doses were selected based on studies that found PPT treatment 
caused estrus-like epithelial cytology (43, 44) and uterine hypertrophy (37).  DPN doses 
were selected based on studies that found it reduced G6PDH and increased the expression 
of progesterone receptor (PR) and androgen receptor (AR) message and protein without 
altering uterine size or the proliferation of luminal epithelial cells (37, 43, 44).  Each drug 
was compounded with enough ≥99% cholesterol (Sigma Aldrich; St Louis, MO) to 
produce a cholesterol pellet with a total weight of 20 mg (45, 46).  Control (CTL) pellets 
contained 20 mg cholesterol alone.  Approximately ten days after ovariectomy (~p70) 
experimental mice were anesthetized under isoflurane gas, and pellets were implanted 
subcutaneously (Figure 2.1).  Mice were randomly assigned to treatment groups prior to 
pellet implantation.   
To compare the efficacy of my doses with previously published work, vaginal 
smears were examined for 8-10 consecutive days following pellet implantation.  Mice 
implanted with LowE, HighE, or HighPPT pellets exhibited vaginal cytology containing 
exclusively, or nearly exclusively, corneated cells, while cytology from CTL, LowDPN, 
or HighDPN-treated animals had zero to very few corneated cells.  Animals treated with 
LowPPT pellets persistently exhibited a mixture of corneated cells, nucleated cells, and 
leukocytes.  Daily wheel running activity was quantified from 10 days to 4 weeks after 
pellet implantation (Figure 2.1), as previously described (20).  During this experimental 
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phase, vaginal cytology was collected every 2 days (dieb. alt.) at varying times during the 
day to avoid providing a non-photic cue.  Cytology for each mouse remained consistent 
throughout the study.  Uterine size was examined at the end of the study (Figure 2.1) to 
further confirm sustained drug pellet efficacy.  Consistent with previous findings (37, 43, 
44), mice administered either dose of estradiol or PPT had increased uterine size 
compared to CTL, LowDPN, or HighDPN mice. 
 
Assessment of daily activity patterns and circadian variables 
Wheel revolutions were detected via a magnetic switch affixed to each cage.  All 
data were recorded in 10-min bins using VitalView and visualized with ActiView (Mini 
Mitter, Bend, OR, USA).  An individual bin was considered active if the total amount of 
activity during that period was equal to or exceeded at least 10% of the animal’s 
maximum daily activity.  The following parameters were assessed in LD: average daily 
activity, the proportion of activity in light vs dark (LD proportion), the distribution of 
wheel running across the total 24 hr day as well as the 12 hr dark phase, acrophase of 
wheel running activity, amplitude, and phase angle of activity onset.  The duration of the 
free running period (τ) and the active phase (α) were determined in animals housed in 
DD. The first 3 days of DD data were ignored to account for potential acute after-effects.  
To evaluate the effect of estrogenic modulation on the responsiveness to light at different 
times of the subjective day, a modified Aschoff’s Type II method (described below) was 
completed with light pulses at times corresponding to the former Zeitgeber time (ZT) 4, 
16, and 22 (ZT 0 and 12 = lights on and off, respectively).  Where possible, animals were 
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used for multiple analyses, and were allowed at least one week to re-entrain following a 
transition from DD to LD. 
For parameters assessed in LD, animals were housed in 12:12 LD conditions for 
at least one week prior to data collection.  Consistent phase angle during the last 4 days of 
this period was required to confirm entrainment (data not shown).  Mean daily wheel 
running activity was determined by averaging the number of wheel revolution per 10 min 
bin for each animal over 3 consecutive days in LD.  Data from each individual animal 
were normalized to pre-pellet baseline, which was similarly calculated by taking the 
mean activity for 3 days in LD post ovariectomy and pre-pellet implantation.  Total 
wheel running activity for each treatment group was then divided by the CTL group value 
to determine fold change. 
To analyze temporal patterning of daily activity across the dark phase, as well as 
in the light compared to dark phase, each 10-min activity bin was averaged over 3 
consecutive days, summed into 1 hr bins, and plotted over time.  To determine the 
distribution of activity within the first and second halves of the dark phase, the average 
wheel revolutions per 10-min bin over 3 days were grouped by treatment, and then 
summed into ZT12-18 and ZT18-24 bins.  The LD proportion describes the number of 
wheel revolutions completed during the light phase (L) compared to the total amount in 
the light and dark (D), and is defined as L/(L+D). 
 Acrophase of wheel running activity in LD corresponds to the time (10 min bin) 
of maximum activity.  It was determined using a cosine fitting function (Actiview) using 
3 days of activity.  Amplitude reflects the difference between the largest activity peak (10 
min bin) and mesor (47) observed from averaging 3 days of wheel running in LD.  
	  	   48	  
Subtracting the mesor from the peak enabled me to compare the magnitude of the rhythm 
in relation to each animal’s baseline activity.  Phase angle of activity onset was 
determined by measuring the difference in minutes between lights off and the onset of 
activity across 5 consecutive days in LD.  Onset was defined as the first 10-min bin of 
activity that equaled or exceeded 10% of the maximum activity peak that was not 
followed by more than 2 consecutive 10-min bins of inactivity (28).  
The length of the free running period (τ) was measured by placing a line of best 
fit through activity onset for the last 5 consecutive days in DD as previously described 
(48, 49).  Minimally, data from the first 3 days of DD were omitted from the analysis to 
limit the contribution of transition effects.  The length of the active period (α) was 
determined by averaging the duration between the time of activity onset and when 
activity stopped over 5 days in DD. Activity cessation was defined as the last 10-min bin 
with wheel revolutions equal to or greater than 10% of peak activity before a break in 
activity lasting 2 or more hours. 
I determined the effect of estrogenic signaling on the behavioral shift in response 
to light pulses at varying times of day (21).  Briefly, animals entrained to 12:12 LD were 
placed in DD for at least 24 hr.  A pulse of light (~290 lx) was given for one hour at times 
corresponding to ZT 4, 16, or 22 followed by 4-6 days in DD.  Shams were treated the 
same, but were not subjected to a light pulse.  The phase shift was calculated as the 
difference between the pre and post pulse onset of wheel running activity.  This 
experimental design allowed me to utilize the uniformity of the entrained animals’ 
subjective day before their free running rhythms drifted (50).  
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Statistical Analyses 
Results are reported as mean ± S.E.M.  For total daily activity, LD proportion, α, 
τ, phase angle, acrophase of wheel running activity, and amplitude, between group 
differences were assessed using one way ANOVAs and/or non-parametric Dunn’s tests 
with treatment group (CTL, LowE, HighE, LowPPT, HighPPT, LowDPN, HighDPN) as 
the independent variable, followed by Tukey post-hoc tests as appropriate.  For phase 
response to light pulses, I used ANOVAs to analyze differences across treatment groups 
within each time point, and to identify differences between non-pulsed and pulsed 
animals receiving the same treatment.  Distribution of activity across the 24 hr day or the 
12 hr dark phase was assessed using 2-way repeated measures ANOVAs with treatment 
and time as independent variables.  All analyses were performed with SigmaPlot 12.0 
(Systat Software, Inc).  Comparisons resulting in a priori value (p) < 0.05 were 
considered significantly different.	  	  
Results 
Estradiol increases total wheel running activity through activation of ESR1, but not ESR2 
The effect of estradiol and selective estrogen receptor stimulation on wheel 
running activity is shown in Figure 2.2A, while total wheel running activity across all 
treatment groups is quantified in Figure 2.2B.  Standardized post pellet activity is 
expressed as fold change compared to pre-pellet CTL.  ESR1 activation played a 
predominant role in the increase in daily activity that occurred following activational 
estradiol treatment.  Both the Low (fold change compared to CTL: 4.233 ± 1.106; 
p<0.001) and HighE doses (fold change compared to CTL: 5.798 ± 1.061; p<0.001) 
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increased relative wheel running compared to CTL (1.00 ± 0.123).  Like estradiol, PPT 
administration increased relative wheel running (fold change compared to CTL: 3.012 ± 
0.459; p<0.001).  HighPPT animals did not differ from LowE or HighE animals (p>0.05 
for all comparisons between HighE, LowE, and HighPPT).  The magnitude of wheel 
running observed in the LowPPT, LowDPN, and HighDPN treatment groups was not 
different from CTL, and was significantly lower than estradiol-treated animals (p<0.05).   
 
ESR1 stimulation mimics the estradiol-induced consolidation of activity to the dark  
All animals housed in LD were more active during the dark phase than the light 
phase (Figure 2.2A,C,E).  To determine whether activational estradiol is sufficient to 
consolidate activity to the dark phase as reported previously (20, 21, 28), I calculated the 
LD proportion.  Both LowE (0.006 ± 0.002; p = 0.02) and HighE (0.004 ± 0.002; p = 
0.008) significantly reduced the LD proportion compared to CTL (0.05 ± 0.01), 
indicating that nearly all wheel running took place during the dark phase in these mice.  
This effect was mirrored by administration of HighPPT (0.006 ± 0.002; p = 0.025).  The 
LowDPN dose had no effect compared to CTL, and nominal reductions observed 
following either LowPPT or HighDPN administration were not significant (Figure 2.2C). 
 
ESR2 activation results in a greater distribution of activity across the dark phase 
Wheel running increased rapidly following lights out in all treatment groups (Fig 
2A,E).  To further assess the effect of estrogen receptor activation throughout the dark 
phase, mean wheel revolutions per treatment group were binned in 1 hr increments and 
plotted over time (Fig 2E).  Two-way repeated measures ANOVA revealed a significant 
	  	   51	  
effect of time (F23 = 107.457, p<0.001) and drug treatment (F6 = 19.022, p<0.001), as 
well as a significant interaction (F138 = 8.706, p<0.001).  Overall, more wheel revolutions 
were completed in the first 6 hours of the dark phase compared to the later night.  
Additionally, mice receiving LowE, HighE, or HighPPT pellets were more active than 
CTL mice throughout the majority of the dark phase.  In contrast, LowPPT animals were 
only more active than CTL animals from ZT14-17.  HighDPN mice were not more active 
than CTL animals overall, but did complete more wheel revolutions at ZT14, 15, and 20 
compared to CTL mice.  At no time were LowDPN mice more active than their CTL 
counterparts.   
Animals treated with estradiol had sustained activity over a greater length of time 
than CTL animals, which completed their maximum amount of wheel running within the 
first 2 hr of darkness.  Further, while HighPPT treatment statistically recapitulated the 
estradiol-induced increase in total wheel running (Figure 2.2B), activity was consolidated 
to the early (ZT12-18), rather than later (ZT18-24), subjective night (Figure 2.2A).  To 
further assess this interaction, I investigated whether ESR1 or ESR2 stimulation 
contribute to when activity occurs during the dark phase.  The total number of wheel 
revolutions completed during the dark phase for each treatment group was summed and 
set at 1.0 (100%).  The fraction of total activity completed during the first (ZT12-18) and 
second (ZT18-24) half of the dark phase was determined and are shown in Figure 2.2D.  
In all treatment groups, except LowDPN, two-way repeated measures ANOVA revealed 
that a greater amount of the total activity was completed from ZT12-18 than from ZT18-
24.  Interestingly, compared to the amount observed in the CTL group (ZT12-18: 0.77 ± 
0.03; ZT18-24: 0.23 ± 0.03), both estradiol doses ([LowE: ZT12-18: 0.64 ± 0.03, p = 
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0.007; ZT18-24: 0.36 ± 0.03, p = 0.007], [HighE: ZT12-18: 0.63 ± 0.04, p = 0.007; 
ZT18-24: 0.37 ± 0.04, p = 0.007]) and DPN-treated animals ([LowDPN: ZT12-18: 0.56 ± 
0.07, p = 0.006; ZT18-24: 0.44 ± 0.07, p = 0.006], [HighDPN: ZT12-18: 0.64 ± 0.05, p = 
0.031; ZT18-24: 0.37 ± 0.05, p = 0.031]) completed a smaller fraction of their total wheel 
running in the first half of the night.  Despite the difference in magnitude of activity 
between PPT and CTL (Figure 2.2B), there was no difference in the temporal distribution 
of activity across the dark phase between these two groups (Figure 2.2D).  
 
Estradiol increases amplitude and delays acrophase of wheel running activity through 
ESR1 and ESR2 activation, respectively 
All of the mice tested demonstrated behavioral rhythmicity with clearly evident 
active and inactive periods (Figure 2.2A).  To assess whether the timing and magnitude 
of these activity patterns were manipulated by selective estrogen receptor stimulation, I 
compared both the phase peak of activity (acrophase of wheel running activity) (Figure 
2.3A,C) and amplitude (Figure 2.3B,C) across treatments.  I found that ESR2 activation 
via DPN shifted the acrophase of wheel running activity, while ESR1 activation via PPT 
increased amplitude.  There was a significant drug effect on acrophase of wheel running 
activity (p = 0.002).  The acrophase for wheel running behavior (Figure 2.3A,C) was 
delayed in animals treated with estradiol (LowE: ZT15.95 ± 0.20; HighE: ZT15.91 ± 
0.21) compared to CTL (ZT14.63 ± 0.16; p<0.05 for both comparisons).  Post-hoc 
analysis revealed a similar effect in animals treated with HighDPN (ZT16.15 ± 0.49; 
p<0.05).   
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Amplitude (Figure 2.3B,C) was higher in estradiol-treated animals compared to 
CTL animals (CTL: 263.14 ± 31.73 wheel revolutions; Low E: 449.06 ± 30.91 wheel 
revolutions, p<0.001; High E: 438.57 ± 21.57 wheel revolutions, p<0.001).  This effect 
was recapitulated by treatment with HighPPT (486.52 ± 37.44 wheel revolutions; 
p<0.001).  Administration of LowPPT (349.63 ± 28.76 wheel revolutions) or either dose 
of DPN (LowDPN: 276.61 ± 32.34 wheel revolutions; High DPN: 350.69 ± 16.81 wheel 
revolutions) failed to modify amplitude compared to CTL.  However, the amplitudes 
observed following these treatments were significantly different from those induced by 
HighPPT (p<0.05 for all comparisons) (Figure 2.3B).  Similarly, the amplitude observed 
in estradiol-treated animals was greater than that observed in LowDPN animals  (p<0.05). 
Overlapping the observed amplitude and acrophase of wheel running activity for each 
treatment group (Figure 2.3C) demonstrates the similarity between estradiol treatment 
and ESR2 activation with respect to acrophase of wheel running activity, and, conversely, 
the role of ESR1 in the increased amplitude induced by Low or HighE treatment. 
 
Estradiol or DPN advances activity onset 
I calculated the mean phase angle of activity onset for each treatment group to 
determine the effects of selective estrogen receptor stimulation (Figure 2.4).  Compared 
to CTL animals, in which activity began 20 ± 4 min after lights off, HighE mice became 
active significantly earlier (9 ± 1 min after lights off; p = 0.0254).  Similarly, both Low (6 
± 3 min) and HighDPN pellets (2 ± 2 min) significantly advanced the phase of activity 
onset (p = 0.029 and 0.002, respectively).  In contrast, selective activation of ESR1 did 
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not alter the phase angle compared to CTL.  Similarly, the low dose of estradiol had no 
effect on phase angle.   
 
Estrogen receptor activation shortens the total period without altering the length of the 
active period 
Under free running conditions (DD), modulation of estrogen receptor activation 
altered period length (Figure 2.5A).  A one-way ANOVA revealed a significant treatment 
effect (p<0.001).  The average period length of animals treated with either dose of E was 
shorter than that observed in CTL animals (CTL: 23.85 ± 0.07 hr; LowE: 23.50 ± .06 hr 
in Low E; HighE: 23.53 ± 0.04 hr; p<0.001 for both comparisons).  A similar effect was 
observed in animals treated with either dose of PPT (LowPPT: 23.62 ± 0.05 hr; p = 0.047 
compared to CTL; HighPPT: 23.55 ± 0.06 hr; p = 0.004 compared to CTL).  HighDPN 
(23.43 ± 0.04 hr), but not the low dose, also decreased τ compared to CTL (p<0.001).  
LowDPN administration had no effect on τ.  However, these mice differed significantly 
from mice treated with LowE (p = 0.021), HighE (p = 0.04), and HighDPN (p = 0.002).  
One-way ANOVA revealed a significant drug effect on the length of the active phase (α, 
p = 0.01) (Figure 2.5B).  However, Tukey post-hoc analysis found no difference between 
CTLs and any other group.  The only difference observed across α was that HighPPT 
animals had a shorter α (482 ± 38 min) than animals treated with the lower dose of 
estrogen (702 ± 17 min; p<0.05). 
 
Estradiol or ESR2 activation attenuate the phase delay associated with a light pulse at 
ZT16 
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I sought to determine the impact of estradiol on behavioral phase response in 
response to photic stimuli.  Mice housed in DD were subjected to a 1 hr pulse of light at 
ZT4, ZT16, or ZT22, or remained non-pulsed (Figure 2.6).  A pulse delivered in the early 
subjective night at ZT16 caused a phase delay of -81 ± 8 min in CTL animals.  Relative 
to CTL mice, there was a significantly dampened delay in animals administered LowE (-
21 ± 12 min; p = 0.002), HighE (-25 ± 13 min; p = 0.005), or HighDPN (-17 ± 8 min; 
p<0.001).  Though PPT at either dose or LowDPN reduced the phase delay compared to 
CTL treatment, the differences were not significant.  Comparisons within each treatment 
group revealed that CTL mice pulsed with light at ZT 16 had a significantly delayed 
activity onset compared to non-pulsed CTL animals (p<0.001).  Similarly, LowPPT 
(p<0.001), HighPPT (p<0.001), LowDPN (p = 0.01), and HighE (p = 0.02) animals 
pulsed at ZT16 exhibited a significant phase delay compared to their non-pulsed 
counterparts.  In contrast, the phase shift observed in LowE or High DPN animals was 
not different from that observed in non-pulsed animals given the same treatment. 
I did not find that estradiol, PPT, or DPN resulted in a behavioral shift in response to 
a 1 hr light pulse administered at other times.  A light pulse during the subjective day 
(ZT4) induced phase advances that ranged between 26 and 63 minutes, but there was no 
treatment effect nor did pulsed animals differ from non-pulsed counterparts.  A 1 hr pulse 
at ZT22, corresponding to the late subjective night, resulted in a relatively large phase 
advance across all groups of animals.  Group means varied from 108 min to 141 min, but 
there were no significant differences.  Within each treatment group, the phase advance 
was significant relative to non-pulsed counterparts (p<0.001 for all comparisons).  
Because the innate free running period in mice is less than the 24 hr day they are 
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entrained to in 12:12 LD housing conditions (51), the non-pulsed sham animals all 
slightly phase advanced (range: 11-25 min across groups).  No difference was observed 
between the treatment groups that did not receive a light pulse.  
 
Discussion 
I tested the hypothesis that estradiol exerts activational control over daily and 
circadian rhythms in female mice.  Further, I sought to differentiate between the roles of 
ESR1 and ESR2 in these behaviors.  I found that ESR1 primarily regulates estradiol-
induced increases in activity magnitude, while ESR2 controls phase and temporal 
distribution of activity.  The total amount and amplitude of wheel running, as well as the 
LD proportion were modulated by estradiol through an ESR1-dependent mechanism.  
Conversely, ESR2 activation delayed acrophase of wheel running activity, distributed 
activity across the dark phase, and advanced phase angle of activity onset.  To the best of 
my knowledge, this is first time estrogenic effects on the acrophase of wheel running 
activity have been demonstrated at all, and certainly the first time that a receptor-
dependent mechanism has been suggested.  Interestingly, mice exhibited a shorter τ when 
either ESR1 or ESR2 were stimulated.  Further, behavioral phase shifts in response to a 
light pulse in the early subjective night, but at no other time, was muted by activational 
estrogen signaling through a mechanism involving ESR2.  These results provide novel 
insight into the activational effects of estradiol, increase our knowledge regarding their 
underlying mechanisms, and provide evidence of the differential roles played by ESR1 
and ESR2.  
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Ogawa et al. (20) demonstrated that ESR1, but not ESR2, loss of function 
prevents the estradiol-induced increase in wheel running activity in both males and 
females. Here I expand upon this work and demonstrate that ESR1 stimulation is 
sufficient to increase total daily wheel running.  Further, I observed an increased activity 
amplitude in mice administered estradiol or HighPPT.  Because entrained mice exhibit 
clear peaks and troughs of activity across a single day in LD, elevations in amplitude are 
expected to coincide with increased total activity assuming the animals remain rhythmic 
as they did here.  It is possible that ESR1 stimulation increases activity levels overall, but 
due to masking effects, the increase is only observed in the dark phase, thus altering LD 
proportion.  I also cannot rule out that increased wheel running itself is enough to drive 
activity-mediated feedback that alters outputs of the master circadian clock, located in the 
suprachiasmatic nucleus (SCN) (52).  Regardless of the locus for controlling activity in 
the current study, these effects can still be considered under the control of ESR1 because 
the only difference across all mice tested was the drug they received.   
The phase angle of activity onset relative to the time of lights-off is advanced in 
intact female rats on the day of estrus when serum estradiol levels peak and progesterone 
levels are at their minimum (17, 53).  It is similarly advanced in female hamsters 
administered estradiol (27), but is unaffected in female Octodon degus treated with 
progesterone (54).  While these data support the hypothesis that increased estrogenic 
signaling strengthens entrainment to light (31), they do not rule out the possibility that 
changes in progesterone signaling may also modulate the phase angle of activity onset.  
Although changes in activity corresponding to the stage of the estrus cycle are well 
documented in rats and hamsters (17, 18, 24, 55), these rhythms have not been observed 
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in mice.  Accordingly, I did not anticipate that selective estrogen receptor stimulation 
would alter phase angle of activity onset in my mice.  However, I found that estradiol 
advanced activity onset by approximately 50% in female mice.  Treatment with DPN was 
sufficient to recapitulate this result, suggesting this is an ESR2-dependent mechanism.  
To my knowledge, no previous report has outlined the relationship between ESR2 and 
phase angle.  Blattner and Mahoney (28) showed that selective removal of classical 
estrogen receptor signaling (mutation of the ESR1 ERE-binding domain in NERKI mice) 
or complete loss of ESR1 failed to alter phase angle, leading to the conclusion that phase 
angle is not regulated by an ESR1-dependent mechanism.  My study also points to a role 
for ESR2-dependent distribution of activity across the dark phase, perhaps accounting for 
the delayed acrophase of wheel running activity observed when this receptor subtype was 
stimulated. 
The length of the free running period under constant lighting conditions is shorter 
in female rats, hamsters, and humans than in males, and is shorter still in females 
administered exogenous estradiol (10, 18, 24, 56, 57).  Recent work using intact WT, 
αERKO, and NERKI female mice found no differences in τ, demonstrating that removal 
of ESR1 signaling does not alter period length (28).  Interestingly, I show here that 
estradiol, both doses of PPT, and HighDPN all shorten τ in a similar manner.  My data 
suggest that stimulation of either ESR1 or ESR2 is sufficient to shorten period, and that 
this effect is activational.  While it is possible that the shortening of τ induced by 
estradiol is ESR1-dependent only and that the dose of DPN administered was high 
enough to act on both receptors, at no time did I observe physiologic evidence of ESR1 
activation in either LowDPN or HighDPN mice.  For example, I did not detect corneated 
	  	   59	  
vaginal cells or uterine hypertrophy in mice treated with DPN.  These data allude to a 
common regulatory mechanism for ESR1 and ESR2’s control of period, but not other 
tested variables in which differential results were produced.  Though unlikely, there also 
exists the possibility that a different estrogen-dependent pathway capable of utilizing all 3 
compounds as ligands, but not directly tested here, is responsible.   
I also measured the length of the active period under constant darkness.  Though 
estradiol had no effect, the higher dose of PPT shortened α compared to LowE animals.  
Interestingly, αERKO mice have a longer α (28), suggesting that the length of the active 
phase is at least partially controlled by estrogenic signaling.  However, in the current 
study α was not affected by circulating DPN alone, a treatment that should have been 
similar to αERKO animals in that only ESR2 is acted on by estradiol.  Because the 
critical difference in these studies is the use of transgenic mice compared to acute 
hormone receptor activation, these date seem to support an organizational, but not 
activational role for estradiol in the regulation of this circadian variable, but warrants 
future developmental research. 
I sought to determine whether estradiol exerts an activational effect on the 
magnitude of light-induced behavioral phase shifting across the subjective day.  I found 
that a light pulse in the late subjective night (ZT 22) resulted in a large phase advance in 
all treatment groups, while light pulses administered in the subjective day (ZT 4) had no 
effect (Figure 2.6).  However, a light pulse in the early subjective evening (ZT 16) 
resulted in a differential response dependent upon treatment.  Because removal of 
endogenous hormone signaling truncates the behavioral phase delay in response to light 
in WT OVX (21) and intact αERKO females (30), I anticipated that mice treated with 
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PPT or estradiol would have a more robust phase delay than CTL animals.  Rather than a 
larger phase delay, I found that estradiol-treated mice had a significantly truncated 
response to a 1 hr light pulse at ZT 16 relative to CTL mice.  Animals treated with DPN 
also had a reduced phase delay when pulsed at ZT16 compared to CTL mice.  These data 
suggest that estradiol exerts an activational effect on phase response to light when the 
pulse is administered in the early subjective night, but no other time, and that this 
response is likely mediated by an ESR2-dependent mechanism.  While these current 
findings are somewhat incongruous with previous studies, they do not take into account 
organizational effects that may also be impacting photic phase responsiveness.  Future 
study is needed to determine the exclusively organizational regulation. 
It remains unknown how estradiol mechanistically enacts these effects on daily 
and circadian activity measures, including whether estradiol acts directly or indirectly on 
central oscillators.  Multiple types of estrogen receptors are expressed within structures 
that input directly or indirectly onto the SCN (7, 58-61) as well as within the SCN itself.  
ESR1 and ESR2 are localized to the SCN in rats and humans (62, 63), though their 
expression is relatively small in mice (64).  There is evidence that GABAergic neurons 
within the SCN express estrogen receptors, especially ESR2 (65), and that estradiol 
administration enhances SCN neuronal excitability (58).  Further, pharmacologic 
GABAA or GABAB receptor agonists injected into the SCN of nocturnal or diurnal 
rodents dampens phase shifting in response to a light pulse in the early subjective night 
(67-69).  Though not directly tested here, these data combined with my current findings 
support the possibility that estradiol blocks the phase delay induced by a ZT16 light pulse 
through an ESR2-mediated mechanism that drives excitability, resulting in greater 
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GABA release, and subsequent GABAA and GABAB receptor binding.  Further work is 
needed to assess the validity of this model. Importantly, the mechanism and the locus of 
action are likely dependent on the specific measure being examined.  For example, 
previous work suggests that estradiol’s effect on total wheel running involves the medial 
preoptic area (mPOA) (20, 63-65), but the involvement of additional structures and 
downstream pathway(s) in this and the other measures reported upon here remain work 
for future study.   
 
Conclusions 
I demonstrate here that estradiol increases total activity and amplitude, reduces 
the LD proportion, delays acrophase of wheel running activity, shortens τ, and dampens 
the light pulse-induced phase shift in wheel running in the early subjective night.  
Importantly, activational stimulation of ESR1 or ESR2 differentially impacts daily and 
circadian activity outputs.  ESR1 regulates estradiol-associated elevations in total wheel 
running activity and amplitude, while also consolidating activity to the dark phase.  
Conversely, ESR2 stimulation more significantly mediates the timing of activity, 
including sustaining more constant levels of activity across the active period, delaying 
acrophase of wheel running activity, advancing phase angle, and occluding the phase 
response associated with a pulse of light in the early subjective night.  Together, my data 
contribute to a more complete understanding of the activational influence of estradiol on 
the expression of daily and circadian rhythms in female mice.  Further, I suggest, for the 
first time, distinct mechanisms by which ESR1 and ESR2 activity shape biorhythmic 
behavior.  
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Figure 2.1.  
 
 
Figure 2.1. Methodological timeline. Postnatal day indicated by p. 
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Figure 2.2. 
Figure 2.2. Effects of estrogenic signaling modification on circadian wheel running 
activity. A, Representative double-plotted actograms depicting the activational effect of 
differential estrogen receptor stimulation on daily wheel running activity in OVX female 
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mice measured for 5 consecutive days in 12:12 light:dark (LD, lights off at Zeitgeber, 
ZT, 12). White and black bars at the top indicate whether the lights were on or off 
respectively.  Consecutive days are plotted on the y-axis, while the ZT over 48 hr is 
shown on the x-axis.  Each black bar represents a 10-min bin, and the height indicates the 
amount of wheel running occurring during the period. B-D, Quantified treatment effects 
on circadian activity (mean ± S.E.M.), including total wheel revolutions per day in LD 
(B), LD proportion (C), and fractional breakdown of total activity occurring during the 
first versus second half of the dark phase (relative activity ZT12-24) (D).  Sample size (n) 
is indicated below each bar.  ♦, ○, ●, and ✚ denote significantly different comparisons 
made to CTL, LowE, HighE, and, HighPPT, respectively.  In panel D, within group 
differences in relative activity ZT12-24 are indicated by *.  One symbol p<0.05, and 2 
indicate p<0.001.  E, Wheel running activity from 3 consecutive days in LD was 
averaged into 1 hr bins.  ♦, ♦♦ p<0.05 and 0.001, respectively, compared to CTL (2-way 
repeated measures ANOVA).  Sample sizes per time points are as follows: CTL (n = 10-
11), LowE (n = 9-10), HighE (n = 11-12), LowPPT (n = 8-9), HighPPT (n = 8), LowDPN 
(n = 7-8), HighDPN (n = 7-9). 
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Figure 2.3. 
 
 
Figure 2.3.  Estradiol increases amplitude through ESR1 and delays acrophase of wheel 
running activity via ESR2. A, Acrophase of wheel running activity averaged over 3 days 
in LD across CTL, LowE, HighE, LowPPT, HighPPT, LowDPN, and HighDPN-treated 
OVX female mice.  Plotted between ZT12 and 18 (mean ± S.E.M.), the sample sizes per 
group are as follows: CTL (n = 10), LowE (n = 10), HighE (n = 11), LowPPT (n = 8), 
HighPPT (n = 8), LowDPN (n = 8), HighDPN (n = 9). ♦♦ denote p<0.001 compared to 
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CTL.  B, Amplitude plotted as the difference between the daily wheel running peak and 
mesor.  Values represent the mean ± S.E.M.  The n per treatment is shown below the 
corresponding bar. ♦, ○, ●, and ✚denote significant comparisons made to CTL, LowE, 
HighE, HighPPT, respectively.  For one symbol p<0.05, and p<0.001 for two.  C, 
Polargram representation of the effects of E, PPT, and DPN administration on acrophase 
of wheel running activity and amplitude.  The radial axis value intersected by a given 
treatment group’s vector corresponds to the acrophase of wheel running activity.  Both 
degrees and ZT are shown.  Vector length is indicative of amplitude magnitude.  
Variance shown in A and B. 
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Figure 2.4. 
 
Figure 2.4. Phase angle of activity onset (mean min ± S.E.M.) for CTL, LowE, HighE, 
LowPPT, HighPPT, LowDPN, and HighDPN-treated animals.  Sample size per treatment 
group is indicated to the right.  ♦ denotes comparisons made to CTL.  For one symbol 
p<0.05, and p<0.001 for two. 
	  	   77	  
Figure 2.5.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5.  Effects of estradiol, PPT, and DPN on τ and α.  A, The mean free running 
period (τ) (± S.E.M.), and B, the average duration of the active period (α) (± S.E.M.).  
Both parameters were determined from 5 days of data from animals housed in DD.  
Samples sizes for each group are indicated below the corresponding bar.  ♦, ○, ●, and ∞ 
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denote comparisons made to CTL, LowE, HighE, and Low DPN, respectively.  For one 
symbol p<0.05, and p<0.001 for two. 
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Figure 2.6. 
 
Figure 2.6.  Photic phase response of OVX female mice treated with estradiol, PPT, DPN 
or CTL.  Entrained animals were housed in DD for 24 hr and were either maintained in 
the dark (No Pulse) or pulsed with light for 1 hr at a time corresponding to the previous 
LD schedule’s ZT4, ZT16, or ZT22.  Values represent the average (± S.E.M.) relative 
difference between the pre and post-pulse onset of wheel running activity.  Negative 
values indicate a phase delay, while positive values signify a phase advance.  Sample 
sizes are shown for each treatment group at each time point.  ♦ denotes comparisons 
made to CTL.  For one symbol p<0.05, and p<0.001 for two.	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Table 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1. Effects of treatment on the presence of corneated vaginal epithelial cells and 
uterine hypertrophy. Categorical analyses of these two measures based on treatment.  
Depending on the measure, an assessment of No indicates that at no time did any of the 
animals in this treatment group present with corneated vaginal epithelial cells or uterine 
hypertrophy, respectively.  Conversely, Yes indicates that corneated cells were always 
present in all animals within this treatment group or that all animals exhibited uterine 
hypertrophy.  Vaginal cytology from some, but not all, of the LowPPT animals contained 
exclusively corneated cells throughout the entire study, while others did not.  
Consequently, these animals were categorically assessed as Inconsistent. 
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Abstract 
Developmental hormone signaling during discrete critical periods organizes the 
adult circadian timekeeping system by altering adult hormone sensitivity and shaping 
fundamental properties of circadian rhythmicity.  However, the timing of when 
developmental estrogens modify the timekeeping system is poorly understood.  To test 
the hypothesis that alterations in perinatal estrogenic signaling organizes the adult daily 
and circadian activity rhythms, I utilized aromatase knock-out mice (ArKO), which lack 
the enzyme required for estradiol synthesis.  ArKO and wild-type (WT) males and 
females were administered either estradiol (E) or oil daily for the first 5 days postnatally 
(p1-5E and p1-5OIL, respectively) because this treatment window encompasses the 
emergence of transcriptional rhythmicity and light responsiveness in the suprachiasmatic 
nucleus, a bilateral hypothalamic structure regarded as the ‘master oscillator’. Following 
sexual maturation, gonadectomy, and exogenous estradiol supplementation, circadian 
parameters were assessed.  I discovered that altered perinatal estrogenic signaling exerts 
organizational control over the expression of daily and circadian activity rhythms in adult 
mice and that these effects are sex-dependent.  Specifically, p1-5E reduced total wheel 
running activity only in mice with low brain estradiol during this developmental period, 
but had no effect on WT male activity levels.  In females, wheel running was 
consolidated by p1-5E to the early versus late evening, a phenomenon characteristic of 
male mice.  The maximum activity peak was reduced by p1-5E in ArKO females only, 
while this treatment advanced the time at which peak activity occurred in females, but not 
males. P1-5E shortened the length of the active phase in WT males, but had no effect on 
ArKO males or females of either genotypes.  Finally, p1-5E altered the magnitude of 
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photic-induced shifts in the phase of activity onset, suggesting that neonatal estrogenic 
signaling impacts circadian behavioral plasticity in adult mice.  Importantly, this work 
expands our knowledge regarding both the critical periods of development of the adult 
timekeeping system and the role that estrogenic signaling plays in the expression of daily 
and circadian activity rhythms throughout life. 
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Introduction 
A circadian rhythm describes a 24 hr period under constant conditions.  While the 
circadian timekeeping system is critical to homeostasis, it does not operate autonomously 
from its environment.  Rather, it is plastic within physiologic limits, allowing for acute 
responsiveness to subsequently integrated cues, including alterations in the length of day, 
light intensity, and peripheral clock-associated feedback.  One such influence on the 
expression of rhythmicity is gonadal hormone signaling.  Substantial sex differences in 
chronobiology (Mong et al., 2011), higher rates of sleep and circadian disruption-
associated pathologies in women (Bailey and Silver, 2013), and altered daily and 
circadian rhythm activity following circulating estrogen modification (Blattner and 
Mahoney, 2014; Royston et al., 2014) strongly suggest a role for estrogenic signaling in 
the regulation of daily rhythms.  
 In addition to the effects of circulating estrogens (Royston et al., 2014), 
developmental estradiol exposure permanently shapes the expression of circadian 
rhythms.  In rodents, peri- and neonatal exposure to estrogens and/or androgens has a 
masculinizing effect on the brain (Phoenix et al., 1959; Arnold, 2009), while the lack of 
these hormones or the sequestration of estrogens by alpha-fetoprotein (Uriel at al., 1976) 
results in a feminized phenotype.  This early life hormonal exposure organizes neural 
circuits and their respective molecular milieu, adjusting hormone responsiveness in the 
adult.  For example, in adult female rats and hamsters, circulating estradiol shortens the 
duration of the free running period.  However, female rodents masculinized by treatment 
with testosterone in the neonatal period fail to shorten τ when administered estradiol as 
adults (Zucker et al., 1980; Albers, 1981).  Further, female mice incapable of 
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synthesizing estrogen exhibit less wheel running activity, but a longer τ than 
ovariectomized (OVX) wildtype (WT) females (Brockman et al., 2011).  While these 
data clearly demonstrate innate differences in circadian activity resulting from aberrant 
estrogenic signaling during development, it remains unknown when the timekeeping 
system is sensitive to or can be disrupted by gonadal hormones.  
 The cytochrome P450 enzyme aromatase is required for the final step in the 
conversion of C19 steroid hormones to estradiol (Nelson et al., 1993).  This enzyme is 
encoded by the cyp19 gene. To investigate the organizational role of estradiol during a 
distinct developmental period on the expression of adult circadian patterns, I utilized 
mice lacking the proximal promoter region and the first 2 exons of the cyp19 gene.  
These mice are unable to produce aromatase, and are therefore incapable of synthesizing 
estradiol, though their ability to respond to exogenous estradiol remains intact (Honda et 
al., 1998).  Aromatase knock-out (ArKO) mice and WT littermates were administered 
either estradiol (E) or peanut oil daily for the first five days of life (p1-5E or p1-5OIL, 
respectively).  This critical period was selected because it encompasses the emergence of 
clock gene rhythmicity (p3-5) (Munoz et al., 2000) and light responsiveness (p4) (Huang 
et al., 2010) within the suprachiasmatic nucleus (SCN), a bilateral hypothalamic structure 
that is both regarded as the ‘master oscillator’ and required for normal circadian activity 
rhythms (reviewed in Welsh et al., 2010).  Following sexual maturation, both male and 
female mice were gonadectomized (GDX) and treated with exogenous estradiol.  
Timekeeping activity variables were then measured to determine the effect of perinatal 
modulation of estrogenic signaling on the adult expression of daily and circadian 
rhythms.  Through this experimental design, I demonstrate here that 1) p1-5E  perturbs 
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specific daily and circadian activity rhythm parameters in adult WT animals, 2) 
developmental estradiol administration to ArKO animals rescues certain WT-like adult 
activity patterns, and 3) that select circadian timekeeping parameters undergo estrogen-
sensitive organization during the first 5 days of life. 
 
Methods 
Animals and Housing 
Circadian activity patterns in intact and GDX male and female ArKO mice have 
been reported previously (Brockman et al., 2011).  The ArKO breeding colony at the 
University of Illinois Urbana-Champaign was originally derived by crossing male and 
female C57Bl/6 mice obtained from Dr. Honda (Fujita Health University, Japan) that 
were heterozygous (+/-) for deletions in the cyp19 1st and 2nd exons, as well as the 
proximal promoter region as described previously (Honda et al., 1998).  All mice used for 
the studies described here were generated by +/- ArKO breeding pairs provided by Dr. 
Bunick (UIUC), and were maintained in accordance with the University of Illinois 
Urbana-Champaign Institutional Animal Care and Use Committee guidelines and the 
NIH guide for the care and use of laboratory animals.  
Pregnant dams were observed daily for the presence of litters.  The day of birth 
was designated as postnatal day 1 (p1). Dams were arbitrarily assigned to have their 
litters treated with E or peanut oil (OIL) when they gave birth to their first litter.  All pups 
were injected subcutaneously (s.c.) at the same time each day for the first 5 days of life 
(p1-5) with 20 µL of either OIL or E in peanut oil (1 mg/mL).  Peanut oil was selected to 
minimize infanticide (Hisasue et al., 2010).  Entire litters received uniform treatments to 
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minimize maternal preference.  All subsequent litters born to each dam received the same 
treatment as the first litter.  Mice used in this study were generated from 6 breeding pairs 
whose litters received OIL and 6 breeding pairs whose litters received E.  Pups remained 
with their dam until they were weaned at p21. 
At weaning, ear tissue was collected from each animal and genotyping was 
performed via PCR as described (Bakker et al., 2002).  Briefly, tissue was combined with 
50 mM NaOH and denaturated at 95 C for 10 minutes, vortexed, and quenched with 1 M 
Tris (pH 8).  Two distinct sets of primers were used to interrogate the extracted DNA for 
either the wildtype (WT) aromatase gene (375 bp; ARK-1/ARK-2) or the mutant gene 
(231 bp; ARK-1/ARK-3).  The sequences used were as follows (5’ to 3’): ARK-1 CGT 
GGG CAG GTG ATC AGT TTA CCA TGT CCT AAT CTT CAC; ARK-2 TCT TCT 
GAG GCC AAA TAG CGC AAG ATG TTC; ARK-3 CTG CTA AAG CGC ATG CTC 
CAG ACT GCC TTG).  WT and homozygous ArKO animals were selected for daily and 
circadian activity analysis. 
Animals were maintained at a constant temperature (22 C) in 12:12 hr light:dark 
(LD) (unless otherwise noted).  Light provided a consistent Zeitgeber across the 24 hr 
day, with Zeitgeber time (ZT) 0 signifying the time of lights on and ZT12 indicating 
lights off.  Food and water were provided ad libitum.  Animals housed within the 
breeding colony were group-housed with same sex littermates from weaning (p21) until 
experimental use.  Breeding animals were provided with Teklad 8604 rodent diet, which 
contains 600 µg/g phytoestrogens (Weber at al., 2001).  Experimental animals were fed 
Teklad 2016 rodent diet because it contains levels of soy estrogen isoflavones, including 
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daidzein and genistein aglycone equivalents that are subthreshold for eliciting biological 
activity (<12 ppm; Harlan Laboratories, 2014). 
 
Gonadectomy and estradiol replacement 
To assess whether estradiol administration during the first 5 days of life alters the 
adult timekeeping system, endogenous sex hormone signaling was disrupted by GDX in 
all experimental animals following sexual maturation (p50).  On the day of surgery, mice 
were deeply anesthetized with ketamine/xylazine (100 mg/kg and 10 mg/kg, respectively; 
i.p.) and maintained with isoflurane gas as necessary.  In females, ovaries were removed 
through bilateral flank incisions, and the muscle/fascia and overlying skin were closed 
with surgical silk and staples.  In males, the testes, epididymis, and epididymal fat were 
bilaterally removed via a vertical incision through the linea alba.  Following GDX, 
animals were singly housed in plastic cages (28 cm L x 16 cm W x 12 cm H). To assess 
gross sexual maturation effects of p1-5E, anogenital distance (AGD) was measured on the 
day of GDX in all animals.  Weights did not vary significantly (data not shown).  
Accordingly, only raw AGD is reported here.  AGD was defined as the distance between 
the anus and the vaginal opening or penis. 
Approximately ten days after ovariectomy, on p60, experimental mice were 
anesthetized under isoflurane gas and pellets containing 50 µg estradiol compounded with 
20 mg ≥99% cholesterol (Sigma Aldrich; St Louis, MO) were implanted subcutaneously 
as described previously (Ogura et al., 2007; Risbridger et al., 2001; Royston et al., 2014).  
During early pilot work, it was discovered that GDX animals receiving no exogenous 
hormone supplementation did not run on their wheels, preventing any between group 
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comparisons. Consequently, I elected to treat all animals with an equal dose of estradiol.  
Activational estradiol robustly increases the magnitude of total daily wheel running 
(Blattner and Mahoney, 2014; Royston et al., 2014).  This experimental approach ensured 
that all adult animals had standardized levels of circulating hormone, allowing me  to 
differentiate between the effects of perinatal estradiol signaling on daily and circadian 
activity outputs.  The use of pellets removed the need for daily hormone injections, which 
may have served as a non-photic cue. The estradiol dose selected increases uterine 
weight, induces estrous-associated vaginal cytology, and alters daily and circadian wheel 
running activity rhythms (Blattner and Mahoney, 2013; Carroll and Pike, 2008; Royston 
et al., 2014).  
Five days after pellet implantation (p65), cages were outfitted with a metal 
running wheel (11 cm diameter) affixed to the cage top.  During the light phase, the 
intensity of light measured at the top of the cage ranged from 220-360 lx (average 290 
lx).  Daily wheel running activity was quantified beginning 10 days after pellet 
implantation, as previously described (Ogawa et al., 2003; Royston et al., 2014).  Wheel 
running data was collected between 10 days and 4 weeks following pellet implantation.   
 
Assessment of daily activity patterns and circadian variables 
A magnetic switch affixed to each cage detected wheel revolutions, which were 
recorded in 10-min bins using VitalView (MiniMitter, Bend, OR, USA).  Data was 
visualized with ActiView (Mini Mitter, Bend, OR, USA).  A bin was considered active if 
the total amount of activity during the 10 min was equal to or exceeded at least 10% of 
the animal’s maximum daily activity.  The following parameters were assessed in LD: 
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average daily activity, the proportion of activity completed in the light vs the dark (LD 
proportion), temporal patterning of activity across the total 24 hr day, acrophase, 
amplitude, and phase angle.  The duration of the free running period (τ) and the active 
phase (α) were determined when animals were housed in total darkness (DD).   
For parameters assessed in LD, experimental animals were housed in 12:12 LD 
conditions for at least one week prior to data collection.  Consistent phase angle during 
the last 4 days of this period was required to confirm entrainment (data not shown).  All 
animals that ran on the provided wheels exhibited evidence of photic entrainment, but 
mice that did not run at all were omitted from the study.  Mean daily wheel running 
activity was determined by averaging the number of wheel revolution per 10 min bin for 
each animal over 3 consecutive days in LD.  The mean values per 10 min bin were 
summed to yield the total wheel revolutions completed during the 24 hr day.  To compare 
the patterning of daily activity over time across treatment groups, each 10 min activity 
bin was averaged over 3 consecutive days and plotted hourly.  Statistical comparisons 
were performed each hour on the hour.  The LD proportion describes the number of 
wheel revolutions completed during the light phase (L) compared to those completed 
during the dark phase (D).  Defined by the formula L/(L+D), an LD proportion close to 1 
is associated with an animal active equally in the light and dark, while a value nearing 0 
is indicative of an entirely nocturnal animal.  Average LD activity over 3 days was used 
to calculate LD proportion.   
Acrophase, the time of peak activity, was calculated with ActiView using the 
observed 3-day LD average of each animal’s wheel running rhythm.  Amplitude reflects 
the difference between the activity peak and mesor observed when daily wheel running 
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was averaged over 3 days in LD.  Phase angle of activity onset was determined by 
measuring the difference in minutes between lights off and the onset of activity across 5 
consecutive days in LD.  Activity onset was defined as the first 10 min bin of activity that 
equaled or exceeded 10% of the maximum activity peak that was not followed by more 
than 2 consecutive 10 min bins of inactivity.   
Behavioral assessments requiring constant darkness (DD) were conducted over at 
least 8 consecutive days.  The first 3 days were omitted from analysis to limit the 
contribution of acute transition effects, and the last 5 days were used for analyses.  The 
length of the free running period (τ) was measured by fitting a line through activity onset 
for 5 consecutive days as previously described (Agostino et al., 2007; Ogeil et al., 2010).  
The length of the active period (α) was determined by averaging the duration between the 
time of activity onset and activity cessation over 5 days in DD.  Activity onset was 
defined as stated above.  Activity cessation was defined as the last 10 min bin with wheel 
revolutions equal to or greater than 10% of peak activity before a break in activity lasting 
2 or more hours. 
 To determine the effects of p1-5E on the magnitude and direction of shifts in the 
phase of activity onset in observed animals subjected to a light pulse at varying times of 
day, I employed a previously described Aschoff type II phase response paradigm 
(Royston et al., 2014).  Briefly, animals were entrained to LD, and released into DD for 
at least 24-hr prior to administration of a 1 hr light pulse (~290 lx).  Pulses were 
administered at times corresponding to ZT4, 16, or 22.  Entrained animals that were 
released into DD, but not pulsed with light, served as shams.  All animals then continued 
in DD for at least 5 days.  The phase shift was defined as the difference between the pre- 
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and post-pulse activity onset.  The average from 3 days prior to and 5 days following the 
pulse were used.  The day immediately following pulse administration was discarded to 
account for acute after effects. 
  
Statistical Analyses 
Results are reported as mean ± S.E.M.  For total daily activity, LD proportion, α, 
τ, phase angle of activity onset, acrophase, and amplitude, between group differences 
were assessed using three way ANOVAs and/or non-parametric Dunn’s test with sex, 
genotype, and drug as independent variables, followed by Tukey post-hoc tests as 
appropriate.  To determine differences in the patterning of wheel running activity across 
the 24 hr day, two-way repeated measures ANOVA with treatment (drug/genotype) and 
time as independent variables were used, followed by Tukey post-hoc test as appropriate.  
Males and females were analyzed separately.  An a priori interest in the effect(s) of drug 
and genotype within each time point negated the need for multiple comparison analyses.  
Sex, genotype, and/or drug-induced effects on phase shifts in activity onset in response to 
light pulse administration were assessed within each time point using three-way 
ANOVAs with the above stated independent variables.  This was followed by Tukey 
post-hoc tests as appropriate.  Two-way ANOVAs followed by similar post-hoc analyses 
were used to identify significant effects of genotype and drug within sex.  Differences in 
the phase response elicited by a light pulse at a given time and non-pulsed counterparts 
within a given sex/drug/genotype combination were assessed with one-way ANOVAs, 
followed by Tukey post-hoc testing as appropriate.  All analyses were performed with 
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SigmaPlot 12.0 (Systat Software, Inc).  Comparisons resulting in a priori value (p) < 0.05 
were considered significantly different.	  	  
Results 
Neonatal estradiol administration alters anogenital distance length in male and female 
mice 
Increased AGD is characteristic of the masculine phenotype (reviewed in Golub 
et al., 2010). Males in the current study had longer AGD than females (F1 = 162.69, 
p<0.001) (Figure 3.1).  Administration of estradiol from p1-5 lengthened anogenital 
distance in WT (6.57 ± 0.17 mm) and ArKO females (6.93 ± 0.32 mm) compared to p1-
5OIL counterparts (WTF+Oil: 6.21 ± 0.28 mm; ArKOF+Oil: 5.65 ± 0.63 mm; p<0.05).  A 
similar and more robust effect was observed in WT males (WTM+Oil: 11.35 ± 0.71 mm; 
WTM+E: 14.27 ± 0.68 mm; p = 0.007).  ArKO males treated with oil (13.76 ± 0.80 mm) 
had longer AGD than oil treated WT males (p = 0.036), an effect potentially accounted 
for by the higher levels of circulating androgen and testosterone present in these mice 
compared to WTs (Bianco et al., 2006).  Administration of p1-5E to ArKO males (10.52 ± 
0.66 mm) restored AGD to levels nearly the same as p1-5OIL WT males.  These findings, 
while not the direct focus of this study, confirm that p1-5E exerted the predicted 
masculinization effect by lengthening AGD in WT males and females of both genotypes.  
Further, the increased AGD observed in ArKO males was rescued to WT levels by p1-5E. 
 
Manipulation of developmental estradiol exposure modulates daily activity patterns in 
WT and ArKO mice 
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Representative activity patterns (actograms) for each treatment group are shown 
in Figure 3.2A.  Female mice were significantly more active than males (Figure 3.2B) (F1 
= 6.88, p = 0.012).  Irrespective of sex, mice treated with estradiol from p1-5 completed 
fewer wheel revolutions per day than mice administered oil (F1 = 31.02, p<0.001).  
ArKO males administered oil (24,580.57 ± 4,739.56 wheel revolutions per day) from p1-
5 were more active than oil-treated WT males (16,405.57 ± 3,628.88 wheel revolutions 
per day, p = 0.026).  However, while ArKO males that received p1-5E (8,279.9 ± 
1,663.98 wheel revolutions per day) completed significantly fewer wheel revolutions per 
day than their oil-treated counterparts (p<0.001), they were as active as WT males 
(p>0.05).  Further, within WT males, p1-5E (12,925.75 ± 3,523.12 wheel revolutions per 
day) did not alter the magnitude of wheel running compared to p1-5OIL (p>0.05).  
Female mice treated with p1-5E ran less than those treated with oil (F1 = 22.758, 
p<0.001) (Figure 3.2A,B).  This pattern was observed in both WT and ArKO mice.  
Specifically, WT female mice treated with oil (27,391.273 ± 3,176.84 wheel revolutions 
per day) were significantly more active than WT female mice administered perinatal 
estradiol (15,949.80 ± 2,507.93 wheel revolutions per day, p = 0.035).  Similarly, within 
ArKO females, those administered oil from p1-5 (36,250 ± 6,784.72 wheel revolutions 
per day) ran more than those treated with estradiol (9,771.833 ± 2,423.79 wheel 
revolutions per day, p<0.001).  No differences were observed between ArKO or WT 
females within either the oil or estradiol treatment groups (p>0.05).  An additional pattern 
evident is that ArKO males resemble both female ArKO and WT mice. Specifically, in 
these three groups of animals, treatment with estradiol early in development results in a 
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decrease in activity levels in adult animals.  In contrast, WT males do not exhibit 
differences in total activity following estradiol treatment.  	  
The proportion of wheel running revolutions completed in the light compared to 
the dark (LD proportion) was calculated to determine if modulation of perinatal 
estrogenic signaling affects nocturnal activity consolidation in adult mice (Figure 3.2C).  
The presence or absence of estrogenic signaling during the first 5 postnatal days had no 
effect on LD proportion.  Estradiol did not perturb this parameter in WT animals or alter 
the LD proportion in estrogen deficient ArKO animals. There was a main effect for sex 
(F1 = 4.979, p = 0.031), and a significant interaction between sex and genotype (F1 = 
4.408, p = 0.041).  Further analyses revealed that wheel running activity was more 
consolidated to the dark phase in female ArKO mice compared to male ArKOs (Figure 
3.2C) (p = 0.006).  Similarly, ArKO males, irrespective of whether they were 
administered oil (0.017 ± 0.007 wheel revolutions) or estradiol (0.024 ± 0.008 wheel 
revolutions) from p1-5 had a higher LD proportion than male WT mice (p = 0.024). 
Further, female mice of both genotypes and drug treatment groups were equally 
nocturnal, and no differences were detected across WT mice, irrespective of drug or sex. 
To determine the effect(s) of p1-5 estrogenic signaling modulation on the 
distribution of activity across the day within males and females, mean wheel revolutions 
observed over 3 days in LD were organized into 1 hr bins and plotted over the 24 hr day 
(Figure 3.2D).  All mice became active following lights off and inactive following lights 
on (Figure 3.2A,D).  Within males (Figure 3.2D), two-way repeated measures ANOVA 
revealed a significant effect of treatment (F3 = 4.454, p = 0.011) and time (F23 = 49.958, 
p<0.001), as well as an interaction between them (F69 = 3.073, p<0.001).  Similar effects 
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were observed within females with respect to treatment (F3 = 9.651, p<0.001), time (F23 = 
64.496, p<0.001), and their interaction (F69 = 5.123, p<0.001).  While the magnitude of 
wheel running across time varied by treatment within males, the general trend of 
temporal distribution was consistent; wheel running was consolidated to the early versus 
later evening.  Within the females, the same trend was observed only within p1-5E 
animals.  Conversely, p1-5OIL animals of both genotypes continued to exhibit a robust 
quantity of activity across a greater amount of the dark phase.  Within both males and 
females, differences in the amount of wheel running activity across time were greater 
between p1-5E and p1-5OIL ArKO animals than between p1-5E and p1-5OILWT animals. 
 
Influence of perinatal estrogenic signaling modification on adult acrophase and 
amplitude 
I calculated acrophase  (Figure 3.3A) to determine if perinatal estradiol signaling 
regulates the time at which peak wheel running activity occurs in adult mice.  Similar to 
the effects observed with respect to total activity, I found that within WT males 
acrophase was not affected by early exposure to estradiol.  Though a strong trend was 
observed between p1-5OIL and p1-5E male ArKO mice, the difference in acrophase 
between them was not significant.  However, within WT and ArKO females, estradiol 
exposure in the first five days of life had a dramatic effect on the timing (phase) of the 
peak in activity.  Specifically, even allowing for the effects of sex and genotype, estradiol 
advanced acrophase compared to oil-treated mice F1 = 12.591, p<0.001).  When WT and 
ArKO females were combined, estradiol administration from p1-5 significantly advanced 
the timing of peak activity compared to oil treatment (F1 = 17.077, p<0.001).  This effect 
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was observed when comparisons were made between WT females treated with estradiol 
(ZT 15.90 ± 0.36) or oil (ZT 16.99 ± 0.22, p = 0.009), as well as between ArKO females 
administered estradiol (ZT 16.01 ± 0.29) or oil (ZT 17.38 ± 0.21, p = 0.007).  No effect 
of genotype was noted within female mice.  Conversely, within males, no statistically 
significant differences were observed across genotype or drug treatment, despite the 
strong trending difference between oil and estradiol-treated ArKO males.  Further, no sex 
differences were observed between males and females. 
The difference between the daily activity peak and mesor was calculated to 
determine treatment-induced effects on wheel running amplitude (Figure 3.3B).  Female 
mice exhibited a greater amplitude than male mice (F1 = 4.251, p = 0.044).  Irrespective 
of sex, animals administered estradiol had a smaller amplitude than those administered 
oil (F1 = 7.956, p = 0.007).  Further analyses revealed that the greatest effect of early life 
estrogenic signaling manipulation on amplitude was observed between ArKO female 
mice treated with estradiol or oil.  ArKO females treated with oil exhibited a significantly 
higher amplitude of wheel running activity (549.967 ± 51.979 wheel revolutions) than 
their estradiol-treated counterparts (382.473 ± 47.012 wheel revolutions, p = 0.023).  
Interestingly, neither group differed from their WT female counterparts, which, in turn, 
did not differ from each other.  No differences were detected within males, regardless of 
drug treatment or genotype. 
 
Estradiol levels during p1-5 do not influence the phase angle of activity onset in adult 
mice 
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The difference between the time of lights off and the onset of activity was 
determined for all treatment groups to assess whether estrogenic signaling during p1-5 
contributes to the strength of photic entrainment (Gorman and Lee, 2002) in adult mice 
(Figure 3.4).  While this parameter is robustly regulated by circulating estradiol and 
activation of ESR2 (Royston et al., 2014; Blattner and Mahoney, 2014), manipulation of 
p1-5 estradiol levels had no effect on the phase angle of activity onset in adult mice.  This 
finding held true across sexes, genotypes, and drug treatments. 
 
Estrogenic signaling between p1-5 modifies circadian rhythm variables measured in 
constant darkness 
I sought to determine the effects of developmental estradiol on endogenous 
circadian parameters.  I measured both the length of the inherent period (τ) (Figure 3.5A) 
and the active phase (α) in mice housed in DD (Figure 3.5B).  Three-way ANOVA 
revealed a significant interaction between sex and genotype (F1 = 10.263, p = 0.002), as 
well as an interaction between sex and drug (F1 = 5.597, p = 0.022) on the regulation of τ 
(Figure 3.5A).  Within males, τ was longer in estradiol-treated mice compared to those 
administered p1-5OIL (F1 = 4.666, p = 0.040).  Further, ArKO males exhibited a longer τ 
than WT males (F1 = 7.833, p = 0.010).  ArKO males administered p1-5E (23.753 ± 0.078 
hr) had the longest τ, which was significantly greater than that observed in their WT 
estradiol-treated counterparts (23.552 ± 0.0534 hr).  Among males, no perinatal effects of 
estradiol were found either within WT or within ArKO mice.  Similarly, within females, 
neither genotype nor developmental estradiol administration influenced period length.  
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However, female ArKO mice, irrespective of drug treatment, exhibited a shorter period 
than male ArKO mice (p = 0.001). 
I then examined variability in the length of the active phase (Figure 3.5B).  A 
three-way ANOVA revealed a drug effect on the length of α (F1 = 8.518, p = 0.005).  
However, neither genotype nor sex influenced the length of the active phase.  Compared 
to WT oil-treated male counterparts (697.429 ± 40.46 min), α was shortened by p1-5E in 
WT males (438.00 ± 104.99 min, p = 0.007).  Within estradiol-treated males, α was 
shorter in ArKO mice (646.455 ± 48.11 min) than in WT mice (p = 0.015).  Manipulation 
of estrogenic signaling during the first 5 days of life had no effect on the length of the 
active phase in female WT or ArKO mice.	  
To determine the effect(s) of sex and manipulation of neonatal estrogenic 
signaling on the behavioral response to photic stimuli, entrained animals were housed in 
DD for 24 hr and then subjected to a 1 hr light pulse at ZT4, ZT16, or ZT22 (Figure 3.6).  
Animals placed into DD, but not pulsed with light served as non-pulsed shams.  No 
differences were observed between sham animals of varying sexes.  Similarly, animals 
subjected to a light pulse at ZT4, a time corresponding to the early part of the light phase 
in the previous LD housing environment, did not exhibit shifts in the phase of activity 
onset that were different than those elicited in non-pulsed sham animals for any treatment 
group.  A significant interaction between genotype and drug  (F1 = 5.577; p = 0.023) was 
observed in animals pulsed at ZT4.  Further, male ArKO mice treated with p1-5OIL (85.6 
± 27.82 min) phase advanced more than their WT counterparts (19.5 ± 11.47 min; p = 
0.023).  No differences between females pulsed at ZT4 were observed. 
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When a light pulse was administered in the early subjective evening (ZT16), a 
larger phase delay was observed in females (F1 = 4.933; p = 0.032) and ArKO mice (F1 = 
5.293; p = 0.026) compared to males and WT mice, respectively.  Male (-63.38 ± 11.35 
min) and female (-90.57 ± 13.72 min) ArKOs receiving p1-5E, as well as WT females 
administered p1-5OIL (-53.82 ± 7.81 min) exhibited a phase shift significantly delayed 
compared to non-pulsed sham animals of the same treatment group (male ArKO p1-5E: 
24.88 ± 12.30 min; female ArKO p1-5E: 0.17 ± 8.40 min; female WT p1-5OIL: 22.00 ± 
6.09 min; p<0.001 for each respective comparison).  Within males, p1-5E increased the 
magnitude of phase delay induced by a ZT16 light pulse (F1 = 4.450; p = 0.047).  A 
similar effect was associated with the ArKO phenotype in females (F1 = 7.938; p = 
0.010).  Further, p1-5E ArKO females exhibited a greater phase delay that their WT 
counterparts when pulsed with light at ZT16 (p = 0.006). 
Administration of 1 hr light pulse at ZT22, a time corresponding to the late 
subjective night, advanced the phase of activity onset in all animals.  However, only male 
ArKOs (126.25 ± 16.55 min) and WT females (60.56 ± 5.80 min) treated with p1-5OIL 
exhibited a phase advance significantly greater than that observed in non-pulsed sham 
animals (male ArKO p1-5OIL: 23.14 ± 10.10 min, p = 0.013; female WT p1-5OIL: 22.00 ± 
6.09 min, p = 0.008).  Within animals pulsed at ZT22, I observed a significant interaction 
between genotype and drug (F1 = 10.891; p = 0.002).  There were no treatment effects 
within males.  However, p1-5E (100.50 ± 19.16 min) substantially increased the phase 
advance induced by a ZT22 light pulse in WT females compared to those treated with p1-
5OIL (60.56 ± 5.80 min; p = 0.032).  Interestingly, the opposite effect was observed in 
female ArKO mice; here, p1-5E (56.00 ± 9.43 min) reduced the phase advance compared 
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to those treated with p1-5OIL (111.00 ± 16.42 min; p = 0.030).  Within oil-treated females, 
ArKO mice exhibited a greater phase advance compared to WT mice (p = 0.017).  
Importantly, the administration of p1-5E to ArKO females reduced the magnitude of this 
phase advance to levels nearly identical to WT females receiving p1-5OIL.	  
 
Discussion 
Perinatal estrogenic signaling in mice plays a robust organizational role in the 
development of both sexual differentiation and adult hormone responsiveness (reviewed 
in Gillies and McArthur, 2010).  In the current study, I investigated whether exogenous 
estradiol administration during a critical period associated with maturation of the SCN 
disrupts the expression of normal daily and circadian activity rhythms in adult male and 
female mice.  Further, I examined whether similar treatment during the same time was 
sufficient to alter these rhythms in mice not exposed to estradiol at any other 
developmental time point.  Finally, I determined which adult biological timekeeping 
variables are sensitive to estrogenic influence during the first 5 days of life.  
I discovered that total daily activity in both adult male and female mice is altered 
by p1-5E, though not uniformly across the sexes (Figure 3.2A).  In males administered 
p1-5OIL, ArKO mice exhibit greater total daily wheel running behavior than WT males.  
The magnitude of total activity in male ArKO mice treated with oil is more similar to that 
observed in female mice, and in accordance with the innate sex differences in total wheel 
running observed in mice in the current and previous studies (Brockman et al., 2011; 
Blattner and Mahoney, 2012).  Interestingly, between males administered estradiol early 
in development, ArKOs have the same amount of average wheel running as WT males, 
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suggesting that estradiol exposure exclusively during this period is sufficient to 
recapitulate the WT masculine phenotype.  Adult WT or ArKO females treated with p1-
5E were less active than their oil-treated counterparts.  These data suggest that, 
irrespective of estradiol levels at other developmental time points, enhanced exogenous 
estradiol exposure during p1-5 in females dampens the previously demonstrated ability of 
estradiol to increase the magnitude of wheel running during the adult phase in females 
(Royston et al., 2014).   
 ArKO males exhibited wheel running behavior that was less nocturnal than what 
was observed in WT males.  Modulation of circulating estradiol from p1-5 did not alter 
this effect, suggesting that either estradiol does not exert an organizational effect on adult 
LD proportion, or that estradiol does have an effect, but that it is not during the perinatal 
period tested.  Robust regulation of LD proportion by circulating estradiol in adult female 
mice has been previously reported (Royston et al., 2014).  The lack of an effect on this 
measurement by perinatal estradiol manipulation suggests that LD proportion is mediated 
by estrogen through an either exclusively activational mechanism or through an 
organizational pathway that is associated with a different critical period.   
 Though not responsible for the amount of activity occurring between the L and D 
phases, estrogenic signaling during p1-5 did, in part, program when wheel running 
occurred during the dark phase (Figure 3.2D).  While activity magnitude varied by 
genotype and p1-5 treatment, male mice were most active in the early evening.  This 
same trend was observed in female mice administered p1-5E.  Conversely, oil-treated 
females of both genotypes continued to exert relatively consistent levels of wheel running 
activity across the dark phase.  These data suggest that concentration of activity around 
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the early evening may be a masculine characteristic, and that p1-5E is sufficient to 
program this trait in female mice.   
 The time at which peak activity occurred in adult female mice of either genotype 
tested was advanced by p1-5E (Figure 3.3A), demonstrating an organizational role for 
estrogen in the control of acrophase.  Interestingly, administration of estradiol to adult 
WT female mice delays acrophase (Royston et al., 2014), suggesting that these 
organizational and activational estrogenic mechanisms may be exerting dichotomous 
effects.  While the effect of p1-5E was not significantly different than p1-5OIL within 
ArKO males, a strong trend toward advancing acrophase was observed.  Combined with 
my findings in females, these data suggest that exogenous elevation in estradiol during 
the first 5 days of life in animals characterized by low brain estradiol levels is sufficient 
to recapitulate the WT male phenotype.  Amplitude (Figure 3.3B), which is increased by 
circulating estradiol in adult female mice (Royston et al., 2014), was reduced in ArKO 
females administered p1-5E.  Similar to the effect of perinatal estradiol on acrophase in 
female mice, p1-5E appears to exert an effect directly opposite to the result observed 
following treatment in adults.  Together these findings suggest that perinatal estrogen 
exposure dampens estradiol responsiveness within these variables in adult female mice. 
 Phase angle of activity onset is advanced by circulating estradiol (Blattner and 
Mahoney 2014; Royston et al., 2014) through an ESR2-dependent mechanism (Royston 
et al., 2014).  Further, this variable is altered in adult male and female WT and ArKO 
mice following GDX (Brockman et al., 2011).  These previous findings support a role for 
estradiol in the regulation of phase angle.  However, combined with the current finding 
that perinatal estrogenic signaling manipulation does not alter adult phase angle of 
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activity onset irrespective of sex, genotype, or drug treatment (Figure 3.4), the role of 
estradiol is likely entirely activational.  Alternatively, it may be exerting an 
organizational effect during a critical period different than the one tested here. 
 Period length is an innate property of the SCN, and is lost following SCN ablation 
(Welsh et al., 2010).  Further SCN-lesioned animals subsequently transplanted with 
exogenous SCN tissue express the graft donor’s circadian period (King et al., 2003, 
Ralph et al., 1990).  Period length across both sexes was relatively unaffected by p1-5E 
(Figure 3.5A), though ArKO males did exhibit a longer τ than either WT males or their 
female counterparts.  These findings suggest that estrogenic signaling during critical 
period(s) other than the one tested here programs adult period length, potentially in 
conjunction with the effects of activational estradiol. 	  
The length of the active phase was shortened by p1-5E administration to WT 
males (Figure 3.5B), demonstrating that elevated estradiol in animals with already 
relatively high neonatal levels disrupts normal α patterning.  This effect was not observed 
within ArKO males, potentially indicating that estradiol in excess of, but not below, WT 
levels in males can alter α in adults.  P1-5E had no effect on α in females.  Similarly, α 
was not altered by activational estradiol modulation in adult females (Royston et al., 
2014), suggesting that the length of the active period in females may not be under the 
control of estrogenic mechanisms.  However, there exists the possibility that lack of 
estrogens during an untested critical period programs adult α; Blattner and Mahoney 
(2012) reported that adult intact female mice in which estrogen subtype receptor 1 
(ESR1) has been removed (αERKO) exhibited a longer active period compared to WT 
females.  
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I used a photic phase response paradigm to discover that p1-5E levels are 
sufficient to program the behavioral response induced by the administration of a light 
pulse at select times of day, and that these effects are sex specific.  As demonstrated 
previously (Brockman et al., 2011; Blattner and Mahoney, 2013; Royston et al., 2014), 
LD entrained mice released into DD phase advanced slightly.  Introduction of a light 
pulse at ZT4 induced a similar phase advance in most treatment groups.  However, male 
mice that developed in the absence of estradiol completely exhibited a much larger phase 
advance at this time than WTs.  This effect was rescued by p1-5E treatment (Figure 3.6), 
suggesting that estrogenic signaling is required during this critical period for the normal 
behavioral response to a light pulse at ZT4 in male mice.   
When the light pulse was administered at ZT16, male mice treated with p1-5E 
exhibited a larger phase delay than those treated with oil.  Because androgens are readily 
converted to estradiol in the male neonatal hypothalamus (Mong et al., 2011), I predicted 
that estradiol-treated males would exhibit the most masculinized wheel running 
behavioral phenotype.  However, females exhibited greater phase delays than males when 
pulsed at this time point, with the largest observed in ArKO females, suggesting that 
males treated with p1-5E are more similar to females than to males receiving p1-5OIL.  
Further complicating the story, elevated levels of circulating estradiol in adult females 
dampens the phase delay associated with a light pulse at ZT16 (Royston et al., 2014).  
Together, these findings may point to an inverted-U where estradiol mediates the 
magnitude of photic phase responsiveness, and that innate masculine and feminine 
phenotypes oscillate around this U in an estradiol dose-dependent manner.  Future study 
is needed to verify this model. 
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Mice subjected a light pulse in the late subjective night responded by advancing 
the phase of activity onset.  No treatment effect was observed in males.  However, the 
increased advanced observed in p1-5E WT females compared to those receiving oil 
indicates that elevated estradiol disrupts adult behavioral responsiveness to a stimulus at 
ZT22.  Interestingly, the opposite effect was observed within ArKO females.  Oil-treated 
ArKO females phase advanced more robustly than WT females receiving the same 
treatment.  Administration of p1-5E to ArKO females returned their phase advance to one 
of similar magnitude as exhibited by WTs.  These findings demonstrate that within 
females, p1-5E is capable of both disrupting normal phase shifting and also rescuing 
altered behavioral responsiveness following a ZT22 light pulse.  
 
Conclusions 
The current study demonstrates that estradiol exerts organizational control over 
select daily and circadian activity rhythms.  Several distinct patterns emerged from my 
data.  First, some variables, despite being estrogen-sensitive (Brockman et al., 2011; 
Blattner and Mahoney 2012; Blattner and Mahoney, 2013; Blattner and Mahoney, 2014; 
Royston et al., 2014), were not altered by p1-5 treatment with estradiol. LD proportion, τ, 
and phase angle of activity onset were relatively unaffected, suggesting that these 
variables are either not sensitive to permanent organization by estrogenic signaling, or 
that estradiol can program them, but not during the critical period tested.  The second 
pattern to emerge was that estradiol during p1-5 in excess of those circulating in WT 
animals disrupts adult expression of certain daily and circadian activity outputs.  For 
example, within WT females, p1-5E reduces total wheel running, concentrates activity to 
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the early evening, advances acrophase, and exaggerates the normal behavioral 
responsiveness to a light pulse in the late subjective night.  Further, WT males treated 
with p1-5E exhibit a shorter active period than those administered oil.  Finally, I show 
here that modulation of estradiol from p1-5 rescues select daily and circadian activity 
outputs disrupted in mice lacking estrogens throughout development.  Disruptions in the 
quantity of total wheel running and behavioral response to a ZT4 light pulse in male 
ArKO mice are returned to WT levels by p1-5E.  Similarly, the increased phase advance 
observed in female ArKOs following a ZT22 light pulse is eliminated by p1-5E.  
Importantly, the work presented here substantially expands our understanding of the 
developmental effects exerted by estradiol and marks the first time its organizational role 
has been investigated across the expression of so many daily and circadian behavioral 
outputs. 
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 Figure 3.1. 
 
Figure 3.1. Anogenital distance (AGD) measured at p50 following p1-5 estradiol 
manipulation. Sample sizes (n) are shown below each bar. * and ** are indicative of 
comparisons where p<0.05 and 0.001, respectively.
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Figure 3.2. 
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Figure 3.2. Effects of organizational estrogenic signaling manipulation from p1-5 on 
circadian wheel running activity. A, Representative double-plotted actograms depicting 
the organizational effect of estradiol (E) or oil treatment on daily wheel running activity 
in GDX WT and ArKO mice measured for 3 consecutive days in 12:12 light:dark (LD, 
lights off at ZT12). White and black bars indicate whether the lights were on or off.  
Consecutive days are plotted on the y-axis, while the ZT is shown on the x-axis.  Each 
black bar represents a 10 min bin, and the height indicates the amount of wheel running 
occurring during the period. B-C, Quantified treatment effects on circadian activity 
(mean ± S.E.M.), including total wheel revolutions per day in LD (B), and LD proportion 
(C).  Sample size (n) is indicated below each bar.  *, and ** denote statistical 
comparisons where p<0.05 or p<0.001, respectively.  D, Wheel running activity from 3 
consecutive days in LD was averaged into 1 hr bins. Sample sizes are indicated in B,C.  
Males and females were separated and differences between treatment groups at each time 
point were determined using two-way repeated measures ANOVAs. * indicates a 
significant difference compared to same sex WT+Oil animals; # indicates a significant 
difference compared to same sex ArKO+Oil animals; + indicates a significant difference 
compared to same sex WT+E animals. 
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Figure 3.3. 
 
 
 
 
 
Figure 3.3. Acrophase and Amplitude in adult mice following developmental estrogen 
manipulation. A, Acrophase of wheel running activity averaged over 3 days in LD across 
male and female WT or ArKO mice administered estradiol (E) or oil from p1-5.  Plotted 
between ZT12 and 18 (mean ± S.E.M.), the sample sizes per group  (n) are as follows: 
Oil/WT/male (7), E/WT/male (7), Oil/ArKO/male (7), E/ArKO/male (11), 
Oil/WT/female (11), E/WT/female (5), Oil/ArKO/female (4), and E/ArKO/female (6).  
B, Amplitude plotted as the difference between the daily wheel running peak and mesor.  
Values represent the mean ± S.E.M.  The n per treatment is shown below the 
corresponding bar.  For both A,B, *, and ** denote statistical comparisons where p<0.05 
or p<0.001, respectively.  
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Figure 3.4. 
 
 
 
 
 
 
Figure 3.4. Phase angle of activity onset (mean min ± S.E.M.) for male and female WT or 
ArKO mice treated perinatally with estradiol (E) or oil.  Sample size per treatment group 
is indicated to the right.   
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Figure 3.5. 
 
 	  
Figure 3.5. Effects of developmental estradiol administration on τ and α.  A, The mean 
free running period (τ) (± S.E.M.), and B, the average duration of the active period (α) (± 
S.E.M.).  Both parameters were determined from 5 days of data from animals housed in 
DD.  Samples sizes for each group are indicated below the corresponding bar.  *, and ** 
denote statistical comparisons where p<0.05 or p<0.001, respectively.  
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Figure 3.6. 
 
 
Figure 3.6. Photic phase response of male and female WT or ArKO mice treated with 
estradiol (E) or oil p1-5.  Entrained animals were released into DD for at least 24 hr and 
pulsed with light for one hr at Zeitgeber time (ZT) 4, 16, or 22.  Sample sizes varied from 
3-11 animals per treatment group per time point.  * and ** denote statistical comparisons 
between treatment groups within a given time point where p<0.05 or p<0.001, 
respectively.  ★ indicates a statistical comparison between a treatment group pulsed at a 
specific time and its non-pulsed sham counterpart where p<0.05.	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CHAPTER 4: Circulating estradiol alters the expression of rhythmic and plasticity-
associated transcriptional networks in the suprachiasmatic nucleus of adult female mice 
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Abstract 
The adult circadian timekeeping system is governed by a master circadian 
oscillator located within the suprachiasmatic nucleus (SCN) of the hypothalamus. Light 
powerfully mediates daily and circadian rhythm outputs and gene expression through 
inputs onto the SCN. Activity and transcription-associated circadian parameters within 
the SCN are also robustly affected by circulating estradiol.  Further, estradiol interacts 
with light in the early evening to modify photic responsiveness in female mice.  Despite 
the observed functional relationship between light, estradiol, and circadian activity 
rhythms, the molecular mechanism(s) underlying these effects in the female central 
nervous system are poorly understood.  In an effort further define these mechanisms, I 
tested the hypothesis that estradiol alters the expression of transcriptional networks 
within the SCN.  I took advantage of a medium throughput gene expression assay capable 
of interrogating multiple transcripts simultaneously.  To ensure that data generated in this 
study would be applicable to published work outlining the effects of activational 
estrogenic signaling on daily and circadian activity rhythms, tissue was collected from 
adult female mice handled identically to those described in Chapter 2.  Specifically, 
ovariectomized (OVX), mice were implanted with a pellet containing either cholesterol 
(CTL) or estradiol (50 µg) and permitted access to running wheels.  In the early 
subjective night, a time when light causes a maximal shift in the timing of rhythmicity, 
animals of both treatment groups were either pulsed with light (1 hr) or allowed to 
continue running in the dark.  SCN were then collected and estradiol and light-induced 
changes in gene regulatory networks were quantified and analyzed.  In the early evening 
estradiol exerts much greater control over the SCN transcriptional milieu than light, and 
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that estradiol overwhelmingly downregulates gene expression compared to CTL animals.  
Further, I identified multiple overlapping gene regulatory networks enriched by estradiol 
and/or a pulse of light, including pathways not previously implicated in estrogen-
dependent message regulation in the SCN.  The work presented here substantially 
advances our understanding of how estradiol and light mediate transcriptional patterning 
within the SCN, and, importantly, provide a framework for future projects aimed at 
further elucidating the molecular circadian machinery. 
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Introduction  
Estrogenic signaling in female mice robustly modifies the expression of daily and 
circadian activity rhythms through both activational (Blattner and Mahoney, 2014; 
Royston et al., 2014a) and organizational mechanisms (Brockman et al., 2011; Blattner 
and Mahoney, 2012; Royston et al., 2014b).  Importantly, circulating estradiol not only 
alters the strength of photic entrainment (Gorman and Lee, 2002; Blattner and Mahoney, 
2014; Royston et al., 2014a) and quantity of daily wheel running (Blattner and Mahoney, 
2014; Royston et al., 2014a), but also dampens photic responsiveness in the early 
subjective night and shortens the length of the endogenous day (τ) (Royston et al., 
2014a). These functions of the timekeeping system are regulated by the suprachiasmatic 
nucleus (SCN) (Welsh et al, 2010).  Widely regarded as the ‘central oscillator’, the SCN 
is a hypothalamic structure located anterior to the optic chiasm (Klein et al., 1991).  This 
structure is necessary for initiating and mediating critical circadian functions, including 
the length of τ, the magnitude and patterning of daily activity, and entraining innate 
rhythms to light signals.  Multiple inputs, including photic excitatory glutamatergic 
signals from the retinohypothalamic tract, converge onto the SCN (Leak et al., 1999; 
Brown and Piggins, 2007), where 10-20,000 heterogeneous neurons integrate highly 
variable neurochemical inputs, and, in turn, innervate an equally diverse set of outputs 
(Welsh et al., 2010). 
The SCN is the neural locus for the endogenous daily rhythmicity.  Circadian 
patterns of behavior, body temperature, and endocrine secretion are disrupted by surgical 
SCN ablation (Welsh et al., 2010).  Importantly, SCN-ablated animals receiving 
transplanted fetal SCN tissue take on the circadian patterns of the graft host (Ralph et al., 
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1990; King et al., 2003), demonstrating a dependence on the SCN for the expression of 
clock-controlled outputs.  Of note, nearly all cells, tissues, and organs express some form 
of transcriptional daily rhythmicity.  Additionally, an estimated 10-20% of all genes are 
expressed with a 24 hr rhythm in a tissue or cell specific manner (Reddy et al., 2006; 
Deery et al., 2009; Doherty and Kay, 2010; Reddy, 2013).  Many of these rhythmic 
functions are not lost following SCN ablation or dissociation (Welsh et al., 2004; Yoo et 
al., 2004).  Rather, peripheral clocks can continue operating for a few days, but critical 
entrainment between these disjointed rhythms ceases and coordinated oscillation fails 
(Tahara et al., 2012).  To accomplish the monumental task of integrating and 
coordinating so many different individual oscillators, the SCN employs numerous 
timekeeping mechanisms, including powerful control over multiple overlapping 
transcriptional and gene regulatory networks (Ueda et al., 2005; Yan et al., 2008).   
The primary oscillatory mechanism utilized by the SCN involves a core delayed 
transcriptional negative feedback loop (Sato et al., 2006; Siepka et al., 2007; Takahashi et 
al., 2008). Circadian Locomotor Output Cycles Kaput (CLOCK)/ Bone Muscle Aryl 
Hydrocarbon Receptor Nuclear Translocator-Like (BMAL) dimers drive transcription of 
the core clock genes Period (Per) and Cryptochrome (Cry) via E-box element binding, 
resulting in increased PER and CRY translation (Welsh et al., 2010).  Following 
dimerization, PER/CRY returns to the nucleus, and negatively feeds back onto its own 
transcriptional machinery.  The proteins themselves are then degraded by Beta-
Transducin Repeat Containing E3 Ubiquitin (β-TrCP1) and F-box and leucine-rich repeat 
protein 3 (FBXL3), which form ubiquitin ligase complexes, and permit the cycle to begin 
anew.  The summation of this transcription/translation feedback loop is the basis for the 
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~24 hour temporal patterning of CLOCK-associated gene expression within the SCN 
(Welsh et al., 2010; O’Neill et al., 2013).  Additional overlapping feedback loops further 
mediate CLOCK-associated gene expression.  For example, Nuclear Receptor Rev-ErbA 
Beta (REV-ERBα), in concert with retinoic acid receptor-related orphan receptor (ROR), 
blocks Bmal1 (also known as Arntl) expression (Crumbley and Burris, 2011), while 
metabolic NAD+/NAMPT (nicotinamide adenine dinucleotide/nicotinamide 
phosphoribosyltransferase)-mediated mechanisms control Clock salvage, actions 
hypothesized to mediate the precision of SCN gene rhythms (Nakahata et al., 2009; 
Ramsey et al., 2009).  
Importantly, canonical CLOCK-associated transcriptional pathways alone cannot 
account for the robust rhythmic control exerted by the SCN (O’Neill et al., 2013).  
Membrane depolarization, Ca2+ signaling, and Ca2+/cAMP regulatory elements (CREs) 
are additional innate and powerful modulators of mammalian timekeeping (Shibata et al., 
1987; Travnickova-Bendova et al., 2002; Ikeda et al., 2003; Lundkvist et al., 2005; Nahm 
et al., 2005; Zhang et al., 2005; O’Neill et al., 2008).  In addition to acting on the SCN, 
these effectors are also rhythmic themselves (de Jeu et al., 1998; Ikeda et al., 2003; 
O’Neill et al., 2008), suggesting both that they are reciprocally modulated by 
timekeeping mechanisms and that non-genomic mediators also contribute to circadian 
function.   
While circulating estrogens are capable of substantially influencing the expression 
daily and circadian activity rhythms (Ogawa et al., 2003, Blattner and Mahoney, 2014; 
Royston et al., 2014a), the molecular pathways underlying these effects are unclear.  
Recent work has demonstrated that, within hypothalamic and cortical neurons, estrogenic 
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signaling and photic stimulation act through non-genomic Ca2+ dependent pathways 
(Colwell, 2000; Wang et al., 2013), and mediate neuronal excitability (Fatehi and Fatehi-
Hassanabad, 2008; Han et al., 2011).  Further, both estradiol and light act as 
transcriptional regulators (Takamata et al., 2011) through pathways that include 
alterations in the SCN expression of the nuclear transcription factor cAMP response 
element binding protein (CREB) (Ginty et al., 1993; von Gall et al., 1998; Kornhauser et 
al., 2002; Abizaid et al., 2004; Sakamoto et al., 2013).   
Because all of these molecular regulatory actions underlie rhythmic SCN outputs, 
and estradiol alters light responsiveness, circadian wheel running rhythms (Royston et al., 
2014a), and SCN gene expression (Abizaid et al., 2004; Peterfi et al., 2004), I sought to 
further elucidate the mechanism(s) underlying the influence of light and estradiol on 
female mammalian timekeeping in the SCN.  To do this, I manipulated circulating 
estradiol levels and light exposure in the early subjective evening prior to collecting 
bilateral SCN samples.  Following RNA extraction and cDNA synthesis, 96 genes 
expressed in the SCN were interrogated for light and/or estradiol-induced expression 
regulation.  Probes were selected against a wide variety of Gene Ontology (GO) classes 
that include genes whose protein products mediate processes including canonical 
CLOCK pathways, transcriptional regulation, and metabolism, as well as neuronal 
excitability and plasticity, allowing me to comprehensively examine the downstream 
effects of estradiol and light on multiple focused gene regulatory networks.   
 
Methods 
 
Overview 
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  SCN RNA was extracted from mice administered estradiol or CTL and then either 
pulsed with light in the early subjective evening or maintained in total darkness.  This 
time of day was selected because it is associated with robust behavioral and neural 
responses to light cues in numerous species (Colwell 1999, Schwartz 1999).  
Additionally, my own work demonstrates that female mice administered estradiol exhibit 
a reduced shift in the phase of activity onset in response to a photic cue administered at 
this time (Royston et al., 2014a).  The RNA was analyzed for changes in the expression 
of 96 genes selected based on a literature search.  The data was used to generate heat 
maps.  Finally, based on the heat maps, I selected several pathways to use for Kyoto 
Encyclopedia of Genes and Genomes (KEGG) analysis.  Details are as follows. 
 
Animals and Housing 
Past work has described alterations in daily and circadian activity patterns in 
OVX WT female mice following estradiol replacement (Royston et al., 2014a).  Mice 
used in the current study were obtained from the same colony and handled nearly 
identically to ensure that any detected alterations in transcript expression could be 
correlated to the behavioral changes previously reported (Royston et al., 2014a).  Briefly, 
estrogen subtype receptor type 1 knock-out (αERKO) heterozygotes on the C57Bl6/J 
background were crossed, and the resulting wild-type (WT) female mice were used.  The 
mice initially used to start the αERKO breeding colony at the University of Illinois 
Urbana-Champaign were a kind gift from Dr. Pierre Chambon (IGBMC, France), and the 
colony has been maintained as described previously (Blattner and Mahoney, 2013) since 
2005.   
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All mice were maintained in accordance with the University of Illinois Urbana-
Champaign Institutional Animal Care and Use Committee guidelines and the NIH guide 
for the care and use of laboratory animals.  Food and water were provided ad libitum, and 
animals were maintained at a constant temperature (22 C) in 12:12-h light:dark (LD) 
(unless otherwise noted).  Animals within the breeding colony were group-housed with 
same sex littermates from weaning (postnatal, p21) until post sexual maturation (p50), at 
which time female experimental animals were singly housed in plastic cages (28 cm L x 
16 cm W x 12 cm H) outfitted with a metal running wheel (11 cm diameter) affixed to the 
cage top. During the light phase, the intensity of light measured at the top of the cage 
ranged from 220-360 lx (average 290 lx).  Experimental animals were fed Teklad 2016 
rodent diet because it contains <12 ppm soy estrogen isoflavones, including daidzein and 
genistein aglycone equivalents.  Even at maximal doses, these levels are subthreshold for 
eliciting biological activity based on the average daily mouse diet (per Harlan 
Laboratories, 2014). 
Daily vaginal cytology was performed on each experimental animal through two 
estrous cycles beginning on p50 to confirm cyclicity prior to OVX.  On the day of OVX 
(p60), running wheels were removed.  Mice were deeply anesthetized with 
ketamine/xylazine (100 mg/kg and 10 mg/kg, respectively; i.p.) and maintained with 
isoflurane gas as necessary.  Ovaries were removed through bilateral flank incisions, and 
the muscle/fascia and overlying skin were closed with surgical silk and staples.  Vaginal 
cytology was examined daily for the next 8-10 days, and verified that experimental 
animals were no longer cycling or exhibiting signs of estrus.  Wheels were returned after 
5 days of post-surgical recovery. 
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Drug Pellets and Administration 
To determine whether circulating estradiol alters gene expression in the SCN, 
mice received either estradiol or cholesterol pellets.  Mice were randomly assigned to 
treatment groups prior to pellet implantation.  Approximately ten days after OVX, on 
p70, experimental mice were anesthetized under isoflurane gas, and pellets containing 
either estradiol (50 µg + ≥99% 20 mg cholesterol; Sigma Aldrich, St Louis, MO) or 
cholesterol alone (CTL; 20 mg) were implanted subcutaneously.  Pellets were produced 
as described previously (Risbridger et al., 2001; Ogura et al., 2007; Royston et al., 2014a; 
Royston et al., 2014b).  The dose selected increases uterine weight, induces estrus-
associated vaginal cytology, and alters wheel running activity and daily and circadian 
activity patterns (Carroll and Pike, 2008; Blattner and Mahoney, 2014; Royston et al., 
2014a).  Vaginal smears were examined for 8-10 consecutive days following pellet 
implantation.  Mice receiving estradiol pellets presented with vaginal cytology containing 
entirely, or nearly entirely, corneated cells, while smears collected from CTL animals had 
zero to very few corneated cells.  During this experimental phase, vaginal smears were 
performed diebus alternis.  Cytology for each mouse remained consistent throughout the 
study.  
Mice continued in LD with free access to their running wheels for 2 weeks after 
pellet implantation.  Previous work demonstrated that adult exposure to estradiol alters 
photic phase response in the early subjective night, but no other time (Royston et al., 
2014a).  To determine the effects of circulating estradiol and light, as well as the 
interaction between them on SCN gene expression, mice were put in DD for 28 hr and 
then either pulsed with light (290 lx) for 1 hr at the time corresponding to Zeitgeber (ZT) 
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16 or maintained in the dark (ZT0 = lights-on and ZT12 = lights-off).  Therefore, I had 
four experimental groups: mice were either treated with estradiol or CTL, and either 
pulsed with light at ZT16 or served as non-pulsed controls.  At the end of the 1 hr photic 
stimulus, all mice were deeply anesthetized under isoflurane gas and rapidly decapitated.  
Whole brain tissue was removed, rapidly frozen, and stored at -80 C.  At this time, 
uterine size was visually examined.  Mice implanted with estradiol pellets had increased 
uterine size compared to CTL mice as reported previously (Royston et al., 2014a; 
Royston et al., 2014b). 
 
RNA extraction and cDNA synthesis 
SCN were bilaterally dissected from each whole frozen brain.  Gene expression 
changes were assessed in a total of 4 samples (n) per treatment group.  To ensure that 
each n contained a sufficient quantity of RNA, and therefore cDNA, to interrogate all of 
the genes of interest, SCN tissue from 4 animals (8 SCN total) were pooled together per 
n.  Therefore, 16 animals per treatment group were used.   
RNA was extracted with RNAqueous-Micro kits (Ambion, AM1931) according 
to manufacturer instructions.  Optional additional micro filter cartridge wash steps were 
completed with ACS grade 100% EtOH, but no further modifications from the included 
protocol were made.  Briefly, 8 individual SCN were lysed in 100 µL lysis solution and 
thoroughly homogenized.  Fifty µL 100% EtOH was added, and the total lysate volume 
was bound to a micro filter cartridge through centrifugation.  The filter was washed 3 
times, and the pure RNA was eluted.  Prior to long-term storage at -20 to -80 C, RNA 
samples were incubated with DNAse at 37 C for 30 min.  A total of 45 µL RNA+DNAse 
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was obtained.  This reaction mix was centrifuged until a DNAse pellet formed, resulting 
in 40 µL of pure RNA.  Nanodrop was used to determine the concentration and purity of 
all samples.  
 For these experiments, 1 µg RNA were required for reverse transcription with the 
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, 4368814). 
According to manufacturer protocol, 100 mM dNTP, random primers, MultiScribe 
reverse transcriptase, RT buffer, and nuclease-free H2O were combined with RNA at a 
1:1 ratio and centrifuged.  The following thermocycler program was used to complete 
cDNA synthesis: 25C for 10 min, 37C for 120 min, 85 C for 5 min, and 4C for ∞.  cDNA 
was stored at -20 C. 
 
TaqMan Low Density Array (TLDA) and analyses 
TaqMan Low Density Array (TLDA) plates (Applied Biosystems) were used to 
assess the expression of 96 transcripts (Table 4.1).  These genes were selected from an 
extensive primary literature search based on the criteria that they are expressed in the 
SCN and have been implicated in estrogenic signaling mechanisms and/or circadian 
rhythms.  Actb, the gene encoding β Actin, was selected as a housekeeping gene.  The 
gene 18s was auto-loaded as a secondary housekeeping gene, but because preliminary 
analyses showed it was regulated by estradiol (data not shown), I chose not to normalize 
any data to this transcript. 
RNAse-free water was combined with 1 µg cDNA to yield 200 uL total volume.  
This quantity was combined with 200 uL TaqMan universal master mix II (Applied 
Biosystems, 4440038).  Plates were loaded, centrifuged, and run with the 7900HT Fast 
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Real-Time PCR system (Applied Biosystems) according to manufacturer 
recommendation.  This design resulted in the combination of 10.42 ng cDNA with each 
probe.  Each sample was run in duplicate.   
Data was visualized with SDS 2.4 (Applied Biosystems).  Threshold cycle (CT) 
values in excess of 22 indicate insufficient message quantity for proper expression 
quantification, and were consequently omitted.  Of the 96 genes examined, only 6 genes 
were excluded, including Aanat, Cartpt, Mtnr1b, Opn4, Pax4, and Prkcb.  All other 
genes are listed in Figure 4.1.  Relative quantification (RQ) values were calculated 
according to the equation: ΔΔ CT =Δ CT, experimental - Δ CT, reference; RQ = 2-ΔΔ CT.  RQ values 
were then used to generate heat maps using HCL algorithms (TM4-MeV4.4), which 
enabled visualization of expression differences across treatments.  DAVID bioinformatics 
resources (Huang et al., 2008; http://david.abcc.ncifcrf.gov) were used to complete the 
gene ontology (GO) and KEGG pathway analyses. 
 
Statistical analyses 
To determine the statistical significance of differences in gene expression induced 
by estradiol and/or exposure to light for 1 hr at ZT16, two way ANOVAs were performed 
for each interrogated gene.  Independent variables were drug treatment (estradiol or oil) 
and light (pulse or no pulse), while RQ values served as the dependent variable.  A priori 
value (p) <0.05 was considered statistically significant. Statistical analyses were 
performed with SigmaPlot 12.0 (Systat Software, Inc.).  All statistical analyses 
concerning enrichment of GO terms and KEGG pathway were computed within the 
DAVID software suite (Huang et al., 2008; http://david.abcc.ncifcrf.gov).  Biological 
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functions were considered significantly overrepresented if the enrichment score (p) 
<0.05. 
 
Results 
 
I sought to identify transcripts within the SCN whose expression is mediated by 
circulating estradiol and/or exposure to light in the early subjective night (ZT 16) in 
female mice.  To enable interrogation of related genes while continuing to pursue 
hypothesis-driven findings and focus the burden of analysis (Brazma et al., 2001), I 
elected to design a medium throughput PCR assay containing 96 distinct probes, 
including housekeeping genes. Genes of interest whose protein products are 1) expressed 
in the SCN and 2) associated with circadian pathways and/or the genomic or non-
genomic signaling pathways downstream of estrogenic activity were selected for 
interrogation following an extensive literature search.  
The identities of all genes that met threshold criteria are shown in the heatmap in 
Figure 4.1 (all interrogated genes shown in Table 4.1).  Because all genes were 
normalized to CTL animals not pulsed with light at ZT16 (CN) to reflect a standard fold 
change, only CTL+pulse (CP), estradiol+no pulse (EN), and estradiol+pulse (EP) are 
shown.  Genes were clustered according to Hierarchical Clustering (HCL) parameters 
(Eisen et al. 1998), and colors were used to indicate fold change in message expression 
compared to CN.  Green indicates that expression was downregulated, while red indicates 
upregulation.  Black informs no change.  Overwhelmingly, gene expression was 
suppressed by estradiol.  In comparison to estradiol, light alone did not induce the same 
magnitude of regulation.  Further, of the less than 15 transcripts that were altered by light, 
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the trend was toward upregulation.  Gene expression patterns observed in animals treated 
with estradiol and pulsed with light at ZT16 more closely resembled what was seen in 
estradiol treated animals that were not pulsed, than oil-treated animals receiving a pulse. 
Bioinformatic sorting of genes of interest with DAVID (Huang et al., 2008; 
http://david.abcc.ncifcrf.gov) revealed significant enrichment of Gene Ontology (GO) 
terms (Table 4.2).  Enriched terms included Rhythmic Processes (p = 3.1 E-33), 
Circadian Rhythms (p = 3.6 E-29), Regulation of Metabolic Processes (p = 2.9 E-16), and 
Regulation of Transcription (p = 3.3 E-14), among others.  I was particularly interested in 
further clarifying the impact of estradiol and a photic cue on the expression of 
transcriptional families associated with Rhythmic Processes, Regulation of Transcription, 
and Metabolic Processes because these are critical responsibilities of the SCN.  To do 
this, I selected for the interrogated genes falling within each of these GO-terms and then 
sorted by treatment group (EP, EN CP).  Following HCL clustering, I generated heat 
maps to describe treatment-associated expression fold changes (Figure 4.2). 
Keeping with the trend observed when all interrogated genes were clustered 
together (Figure 4.1), estradiol exerted a primarily down regulatory effect on gene 
expression throughout all 3 GO terms, irrespective of whether light was present or not 
(Figure 4.2).  Sorting genes of interest by GO term allowed me to focus on transcript-
specific expression regulation.  For example, the expression of Egr3, the message 
encoding Early Growth Response 3 protein (EGR3), a C2H2-type zinc-finger protein 
important for rhythmic gene expression (Porterfield and Mintz, 2009), is not altered by 
either a light pulse at ZT16 or estradiol, but is robustly increased by both light and 
estradiol.  Additionally, the expression of Estrogen Subtype Receptor 2 (Esr2; formerly 
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ERβ) was downregulated by estradiol treatment, but is not affected by light.  
Interestingly, Estrogen Subtype Receptor 1 (Esr1; formerly ERα) is similarly 
downregulated by estradiol, but is stimulated by light.  
I was interested in which GO terms were enriched within groups of genes 
regulated by the same treatment in the same direction.  To complete this analysis, I 
grouped all significantly regulated genes by effective treatment.  I then sub-grouped them 
by direction of change.  This created the following groups (Table 4.3): genes whose 
expression was repressed by estradiol; induced by estradiol; repressed by a light pulse; 
induced by light pulse, or decreased by a light pulse and estradiol.  These groups of genes 
were subjected to DAVID analysis (http://david.abcc.ncifcrf.gov; Huang et al., 2008), 
and the most enriched biological functions were identified.  Genes associated with 
‘Circadian Rhythms’ and ‘Rhythmic Processes’ were overwhelmingly repressed by 
estradiol administration (p = 5.5 E-15 and 1.5 E-11, respectively) (Table 4.3).  Expression 
of transcripts falling within these categories and regulated by estradiol and light were 
also reduced (p = 1.7 E-7 and 1.0 E-6, respectively).  ‘Regulation of Transcription’ was 
significantly enriched within genes repressed by estradiol (p = 1.4 E-8), induced by 
estradiol (p = 2.7 E-2), or reduced by estradiol and a light pulse at ZT16 (p = 2.9 E-3). 
‘DNA Binding’ was also enriched in genes whose expression was significantly enhanced 
by estradiol (p = 1.8 E-2), while genes associated with ‘Regulation of Metabolic 
Processes’ (p = 3.3 E-10), ‘Protein and Amino Acid Phosphorylation’ (p = 3.6 E-8), and 
‘MAPK Signaling Pathways’ (p = 3.4 E-7) were downregulated by estradiol. 
A pulse of light at ZT16 to CTL animals resulted in very different GO term 
enrichment compared to estradiol treatment (Table 4.3).  Rather than mediating 
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transcriptional mechanisms, genes downregulated by light were significantly associated 
with ‘Neurotransmitter Binding’ (p = 1.8 E-2), ‘Neurotransmitter Receptor Activity’ (p = 
1.8 E-2), and ‘Cell Membrane’ (p = 1.8 E-2).  Transcriptional mechanisms were enriched 
within genes whose expression was induced by light.  These biological functions, unlike 
those altered by estradiol administration, were closely associated with only early 
transcriptional regulation, and include ‘Fos Transforming Protein’ (p = 1.4 E-3) and 
‘bZIP Transcription Factors’ (p = 9.1 E-3).  The biological function ‘Neuropeptide’ was 
also enriched within genes significantly upregulated by light at ZT16 (p = 5.0 E-3).  This 
GO term (GO:0007218) is a child term of various cell surface receptor-mediated 
cascades, and is upstream of nuclear-associated mechanisms 
(http://david.abcc.ncifcrf.gov), but whether the regulated transcripts within this term 
directly mediate early transcriptional activity is not known. 
I began this experiment interested in regulatory gene networks, as opposed to the 
impact of estradiol and light on the expression of individual genes.  To identify pathways 
in which interrogated genes were significantly regulated, as well as the specifically 
altered components within each pathway, I completed KEGG analysis with DAVID 
(http://david.abcc.ncifcrf.gov; Huang et al., 2008).  The most enriched pathways (Table 
4.4) included ‘Circadian Rhythms’ (p = 2.9 E-9), ‘MAPK Signaling Pathways’ (p = 3.4 
E-7), ‘Neurotrophin Signaling Pathways’ (p = 3.7 E-5), and ‘Long Term Potentiation’ (p 
= 3.8 E-4).  I mapped out each pathway and laid my regulated genes of interest within the 
functional output (Figures 4.3-4.6).  Because the regulated areas within a given pathway 
(indicated by a red star) may be in reference to a protein product, downstream target, or 
upstream effector, a table of significantly regulated transcripts within each KEGG 
	  	   137	  
pathway was also generated.  The effecting treatment, direction of change, and statistical 
significance for each gene are indicated. 
Interrogated genes associated with the KEGG pathway ‘Circadian Rhythm’ were 
generally repressed by estradiol.  No genes were regulated by light alone.  However, 
Bhlhe41 (p = 0.001), whose protein product, DEC2, acts as a directly competitive 
CLOCK gene transcriptional repressor (Honma et al. 2002; Sato et al. 2004), Nr1d1 (p = 
0.013), the gene encoding REV-ERBα, and Cry2 (p<0.001) were downregulated by 
estradiol combined with a light pulse at ZT16.  Npas2, a basic helix-loop-helix PAS 
family transcription factor regarded as one of the most critical circadian transcriptional 
regulators (DeBruyne et al., 2007), but no other interrogated gene in this pathway, was 
induced by estradiol (p <0.001).   
There was substantial overlap of enriched genes of interest associated with 
‘MAPK Signaling Pathways’ (Figure 4.4), ‘Neurotrophin Signaling Pathway’ (Figure 
4.5), and ‘Long-Term Potentiation’ (Figure 4.6).  All significantly regulated genes 
associated with these pathways within my model were downregulated.  Genes encoding 
growth factors whose expression was suppressed included Bdnf (p = 0.023), Egf 
(p<0.001), Fgf (p<0.001), Tgfa (p<0.001), Tgfb1 (p<0.001), and Vegfa (p<0.001), whose 
protein products are Brain Derived Neurotrophic Factor (BDNF), Epidermal Growth 
Factor (EGF), Fibroblast Growth Factor (FGF), Transforming Growth Factor Alpha 
(TGFα), Transforming Growth Factor Beta 1 (TGFβ1), and Vascular Endothelial Growth 
Factor A (VEGFA, respectively.  Expression of the transcript encoding a key 
neurotrophin receptor and the receptor showing the highest binding affinity for BDNF, 
Ntrk2 (protein: Tyrosine Kinase Receptor B; TrkB) was also repressed (p<0.001).   
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Within the mammalian CNS, ligand-neurotrophin receptor binding, including 
BDNF-TrkB, induces receptor homodimerization, autophosphorylation within 
intracellular tyrosine residues, and the subsequent initiation of multiple cell signaling 
cascades.  These varying pathways ultimately lead to increased neuronal structural 
plasticity via activation of the mitogen-activated protein kinase (MAPK) pathway and the 
transcription factor CREB, greater synaptic plasticity via activation of the protein kinase 
C (PKC) pathway, and enhanced transcriptional plasticity via pathways that increase 
activation of nuclear factor-	  κB (NFκB) and early activation genes such as JUN 
(comprehensively reviewed in Yoshii and Constantine-Paton, 2010).   
I found that estradiol or estradiol combined with a ZT16 light pulse not only 
suppressed expression of the transcripts encoding the effector neurotrophins and their 
receptors, but also reduced the message for the several of the pathway end points and 
critical mediators.  For example, transcript expression of Creb1 (p<0.001), Creb3 
(p<0.001), Jun (p<0.001), MapK14 (p = 0.018), MapK3 (p<0.001), Nfκb1 (p<0.001), and 
Prkaca (p<0.001), whose protein product cAMP-Dependent Protein Kinase Catalytic 
Subunit Alpha (PKA C-α) is proportionally reflective of PKC activity, were all reduced 
by either estradiol or estradiol combined with a ZT16 light pulse (Figures 4, 5, 6).  
Further, downstream of neurotrophin receptor activation, the PKC cascade potentiates 
synaptic plasticity, in part, by enhancing intracellular bioactive stores of Ca2+.  In 
addition to the observed decrease in PKC pathway players already stated, I also found 
that estradiol reduced the expression of genes encoding multiple neuron-associated Ca2+ 
regulatory proteins in the SCN of female mice, including Calb1 (p<0.001), Calb2 
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(p<0.001), Camk2b (p<0.001), Camk2d (p<0.001), and Camk2g (p<0.001) (Figures 
4.5,4.6). 
Importantly, stimuli beyond neurotrophin-receptor binding can also initiate these 
plasticity-associated pathways.  Glutamate, for example, induces time and dose-
dependent long-term potentiation (LTP) in the SCN (Nisikawa et al., 2002). Similarly, 
Tumor Necrosis Factor (TNF) activates NFκB through a mechanism separate from the 
TrkB-dependent phosphorylation mechanism previously described.  The expression of its 
message, Tnf, was downregulated by estradiol (p<0.001).  Taken together, the results 
shown here demonstrate that estradiol substantially reduces plasticity-associated 
molecular mechanisms through, often redundant, repression of transcripts encoding 
ligands, receptors, mid-pathway regulatory components, and downstream targets.  
 
Discussion and Future Directions 
 Using a medium throughput gene expression array, I discovered that 
estradiol exerts greater control over the expression of gene regulatory networks in the 
SCN than is exerted by light.  Further, estradiol primarily downregulates gene expression, 
though not uniformly.  Estrogenic signaling strongly influences the patterning of daily 
and circadian activity rhythms (Royston et al., 2014a).  However, the impact of 
circulating estradiol on gene expression in the transcriptionally-dependent SCN, a 
structure demonstrated to mediate the expression of daily biorhythmic outputs has not 
been well characterized until now.  I focused on a single time point in the early subjective 
night because the timekeeping system of nearly all species alters its rhythmicity in 
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response to photic cues at this time.  Further, my previously published work shows that 
estradiol alters light responsiveness at ZT16 (Royston et al., 2014a).   
Two noteworthy findings were the light pulse-induced increase in the canonical 
estrogen receptor ESR1, but not ESR2, and the robust induction of the immediate early 
gene Egr3 in mice treated with estradiol and pulsed with light at ZT16. The ability of 
light to induce changes in the expression of ESR1, but not ESR2, suggests that only ESR1 
is photosensitive.  It also provides unique insight into the potential network-based 
relationship between light and estrogenic signaling in the SCN.  While ESR1 is not 
robustly expressed in the SCN, the cells that do express it are found only in the core in 
mice.  Interestingly, photic information inputs onto the SCN core via the RHT (reviewed 
in Silver and Bailey et al., 2014).  Conversely, ESR2 has been detected in shell neurons 
exclusively (Vida et al, 2008).  Future joint electrophysiologic and biochemical studies 
aimed at differentiating between the effects of direct photic input onto SCN core neurons 
on the induction of ESR1 expression and indirect light-induced ESR1 transcription via a 
mechanism reliant on any number of the peripheral SCN inputs described in Chapter 1 
will further clarify the underlying pathway.  Similar studies may also elucidate the 
mechanism by which estradiol increases neuronal excitability in the SCN (Fatehi and 
Fatehi-Hassanabad, 2008).  In the current study, light in the early subjective night 
suppressed genes involved in the regulation of neuronal excitability and transmission, 
while increasing ESR1.  Future studies utilizing estrogen receptor-specific agonists and 
photic or photic-like input may aid in deciphering the mechanisms by which both light 
and estrogenic signaling modify SCN excitability. 
	  	   141	  
Egr3, an immediate early gene, is believed to act as a transcriptional regulator in 
the SCN in response to retinal input (Morris et al., 1998).  In fact, the overall enrichment 
of transcription and DNA binding-associated GO terms by estradiol suggests that the 
hormone exerts fine tuned control over transcriptional machinery in the SCN.  Further, 
that estradiol treatment also mediates the expression of genes affiliated with metabolism, 
phosphorylation, and MAPK signaling support a role for this hormone in the regulation 
of post-translational modification and cell signaling within the SCN. Interestingly, recent 
work has suggested that, while the SCN is both transcriptionally and translationally 
dependent for the expression of circadian rhythms, the regulated message and protein 
networks need not fully overlap (reviewed in O’Neill et al., 2013).  Future studies should 
focus on the proteomics induced by light and estradiol throughout the subjective day to 
differentiate between gene and protein-based requirement for the adult timekeeping 
system. 
When estradiol and/or light-regulated genes were mapped onto KEGG pathways, 
the trend of transcript suppression by estradiol continued to be prominent.  Interestingly, 
within the ‘Circadian rhythm’ KEGG, estradiol differentially regulated Clock and Npas2, 
which encode circadian rhythm-affiliated transcription factors.  Clock and Npas2 appear 
to act through initially overlapping mechanisms (DeBruyne et al., 2007), though the 
complete differentiation of their downstream pathway(s) has yet to be fully elucidated.  
Because Npas2 expression was induced, while Clock’s was repressed, it is possible that 
the current results indicate an estradiol-mediated preferential selection of the Npas2-
associated transcriptional mechanism over the downstream effects of Clock.  Future 
studies are necessary to test this hypothesis. 
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Other significantly overrepresented KEGG pathways included ‘MAPK signaling’, 
‘Neurotrophin signaling’, and ‘Long-term potentiation’.  All 3 of these pathways are 
strongly associated with neuronal and synaptic plasticity, and, accordingly, there was 
substantial overlap of enriched genes. Importantly, MAPK signaling itself is necessary 
for both neurotrophin signaling and LTP.  Further, in studies using rats and mice, MAPK 
is also required for photic-induced phase shifts in activity onset and activation of clock 
genes in the SCN (Butcher at al., 2002; Coogan and Piggins, 2003; Dziema et al., 2003).  
Additionally, the MAPK pathway both inputs onto the central oscillator and is a direct 
timekeeping output (Goldsmith and Bell-Pedersen, 2013), further supporting a role for 
this signaling mechanism in circadian plasticity.  My finding that estradiol downregulates 
genes encoding feed forward components of the MAPK pathway (Figure 4.4) indicates 
that increased estrogenic signaling may impede SCN plasticity.  However, no work to 
date has examined the role of estradiol on the expression of the MAPK pathway within 
the SCN.   
Protein Kinase A (PKA) signaling, which contributes strongly to MAPK 
amplification, and, consequently, neurotrophic signaling and LTP as well, may provide a 
relatively novel target to further explore the relationship between estradiol, circadian 
behavioral plasticity, and MAPK.  I found that administration of both estradiol and a light 
pulse reduced the expression of the transcript encoding PKA C-α.  PKA C-α is the 
structural subunit of the powerful cell-signaling mediator PKA, and due to the reciprocal 
relationship between them, is also indicative of PKC activity.  Blockade of PKA in the 
SCN inhibits glutamate-induced elevations in Per1 expression and attenuates phase 
shifting in the early subjective evening in vitro (Tischkau et al., 2000).  Glutamate is 
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often used in place of light stimuli in vitro.  Interestingly, my own published work 
demonstrates that estradiol dampens behavioral phase shifting following a light pulse 
administered in the early subjective night (Royston et al., 2014a).  Together, these 
findings suggest that a reduction in PKA, such as that induced by estradiol in the current 
study, may dampen molecular and behavioral photic responsiveness.  
To test the hypothesis that estradiol modifies behavioral plasticity in the early 
subjective night through a mechanism that involves reduced PKA activity, I would create 
mice with inducible PKA silencing (null) and overexpression (oe) in an SCN-specific 
manner.  I would then repeat the phase response experiment described in Chapter 2 
(Figure 4.6) with the following treatment groups: WT+CTL, WT+E, 
induciblePKASCNnull+CTL, induciblePKASCNnull+E, induciblePKASCNoe+CTL, and 
induciblePKASCNoe+CTL.  If PKA suppression in the SCN is responsible for the 
estradiol-induced dampening of behavioral plasticity following a light pulse at ZT16, 
then estradiol administration to PKASCNoe mice should not recapitulate its effects in WT 
mice.  Similarly, PKASCNnull mice should mimic WT+E mice with respect to this measure 
regardless of whether they receive CTL or estradiol.  This experimental design is highly 
speculative, however, because an SCN-specific target is currently unknown. 
Aside from MAPK signaling contributions, neurotrophin signaling generally 
mediates neuronal survival.  Because of strong evidence that estrogen is neuroprotective 
(Scott et al., 2012; Spence and Voskuhl, 2012), I anticipated that estradiol administration 
would increase the expression of genes encoding neurotrophic factors and their respective 
receptors.  Rather, I found the opposite to be true; estradiol exerted a repressive effect on 
several of these transcripts and none were enhanced (Figure 4.5).  Of note is the 
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inhibition of Bdnf expression by estradiol and light.  BDNF mediates the magnitude of 
excitatory N-methyl-D-aspartate (NMDA) receptor-associated glutamatergic currents in 
the SCN (Kim et al., 2006; Michel et al., 2006).  It is possible that the reduction in Bdnf 
following estradiol and a light pulse (Figure 4.5) results in neuroprotective effects within 
the SCN by dampening NMDAR-mediated synaptic currents, thereby preventing 
potentially cytotoxic neuronal hyperexcitability. However, the existence of 
predominantly GABAergic population within this structure dictates the need for 
functional electrophysiologic analysis of this hypothesis.   
Similar studies may also reveal more detail about the role of LTP in the SCN.  
While well documented in cortical, cerebellar, and limbic structures, only 4 published 
studies focus on LTP in the SCN (Nishikawa et al., 1995; Nishikawa et al., 1998; 
Fukunaga et al., 2002; Nishikawa et al., 2002).  LTP describes the strengthening of 
synaptic efficiency by repetitive activity, and is perhaps the most robust demonstration of 
synaptic plasticity.  Both the MAPK signaling pathway, and extracellular signal-regulated 
kinase (ERK) in particular (Winder et al., 1999; Kelleher et al., 2004; Jin and Feig, 
2010), and NMDAR are required for the expression of LTP in the SCN (Nishikawa et al., 
1998).  ERK, encoded by the gene Mapk3, is repressed by estradiol in the current study.   
Further, though BDNF is not directly affiliated with the LTP KEGG pathway, the 
implication of its control over NMDAR-mediated synaptic currents (Kim et al., 2006; 
Michel et al., 2006), its ability to activate ERK (Shimizu et al., 2007; Wang et al., 2014), 
and its downregulation following estradiol and light administration (Figure 4.5) warrant 
further investigation into the role it plays in LTP within the SCN.  Recent work 
demonstrates that BDNF, in addition to inducing ERK activation through a 
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phosphorylation-dependent mechanism, simultaneously reduces suprachiasmatic nucleus 
oscillatory protein (SCOP) through calpain-mediated degradation (Wang et al., 2014).  
SCOP inhibits the activation ERK by trapping its precursor in an inactive state (Shimizu 
et al., 2003).  SCOP was not interrogated in the current study.  Therefore, whether it is 
induced by estradiol remains work for future studies.  Importantly, the data shown here 
continue to strongly support an inhibitory role for estradiol with respect to LTP and 
synaptic plasticity in the SCN in the early subjective evening, and provide evidence for 
future studies aimed at further mechanistic clarification. 
 
Conclusions 
Estradiol reduces behavioral phase shifting in response to a light cue in the early 
subjective night.  I demonstrate here that at this same time estradiol also significantly 
alters the transcriptional milieu within the SCN, a structure required for normal circadian 
responsiveness, and does so primarily through downregulation of genes known to 
contribute to neuronal and synaptic plasticity.  By using a hypothesis-driven approach to 
select genes of interest, I have allowed for targeted identification of potential transcripts 
whose estradiol-mediated alteration in expression may contribute to the hormone’s ability 
to alter behavioral plasticity.  These targets serve as a springboard for future work aimed 
and linking genes and behavior.
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Table 4.1. List of genes selected for interrogation. 
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Table 4.2. Summary of Gene Ontology (GO) terms enriched within interrogated genes. 
	  	   159	  
 
Table 4.3. Summary of Gene Ontology (GO) terms significantly enriched within groups 
of genes regulated in a specific direction by estradiol and/or a light pulse at ZT16.   
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Table 4.4. Summary of enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathways within regulated interrogated transcripts. 
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Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Clustered heat map representation of SCN genes interrogated following 
administration of CTL or estradiol and a ZT16 light pulse or no pulse.  The relative 
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quantification (RQ) for each gene of interest per treatment group is colored to indicate 
fold change compared to the CTL/non-pulsed group (CN) (CTL/pulsed = CP; 
Estradiol/non-pulsed = EN; Estradiol/pulsed = EP).  Green indicates a reduction in 
expression, while red indicates induction.  Black is associated with no change.  An HCL 
algorithm determined within TM4-MeV4.4 was used to cluster genes based on functional 
properties and target distance.  
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Figure 4.2. 
 
 
Figure 4.2. Clustered heat map representation of interrogated genes that contribute to 
Rhythmic Processes, Regulation of Transcription, or Metabolic Processes across 
treatment groups.  The relative quantification (RQ) for each gene of interest per treatment 
group is colored to indicate fold change compared to the CTL/non-pulsed group (CN) 
(CTL/pulsed = CP; Estradiol/non-pulsed = EN; Estradiol/pulsed = EP).  Green indicates a 
reduction in expression, while red indicates induction.  Black is associated with no 
change.  An HCL algorithm determined within TM4-MeV4.4 was used to cluster genes 
based on functional properties and target distance.  
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Figure 4.3. 
Figure 4.3. KEGG pathway enrichment analysis of regulated genes identified within the 
Circadian Rhythm pathway. Only significantly regulated transcripts of interest (p<0.05) 
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are shown.  Pathway enrichment is indicated by a red star, while the direction in which 
the specific transcripts were altered and by which treatment are shown in the table.  
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Figure 4.4. 
 
Figure 4.4. KEGG pathway enrichment analysis of regulated genes identified within the 
MAPK Signaling pathway. Only significantly regulated transcripts of interest (p<0.05) 
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are shown.  Pathway enrichment is indicated by a red star, while the direction in which 
the specific transcripts were altered and by which treatment are shown in the table. 
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Figure 4.5. 
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Figure 4.5. KEGG pathway enrichment analysis of regulated genes identified within the 
Neurotrophin Signaling pathway. Only significantly regulated transcripts of interest 
(p<0.05) are shown.  Pathway enrichment is indicated by a red star, while the direction in 
which the specific transcripts were altered and by which treatment are shown in the table. 
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Figure 4.6. 
 
Figure 4.6. KEGG pathway enrichment analysis of regulated genes identified within the 
Long-Term Potentiation pathway. Only significantly regulated transcripts of interest 
(p<0.05) are shown.  Pathway enrichment is indicated by a red star, while the direction in 
which the specific transcripts were altered and by which treatment are shown in the table. 
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In this thesis, I wanted to test the global hypothesis that estradiol exerts both a  
developmental and adult role on the expression of rhythmic behavioral and 
transcriptional outputs.  The work shown here demonstrates that estradiol exerts both 
activational and organizational effects on the expression of daily and circadian activity 
rhythms in mice.  These data are the first to show that acutely circulating estradiol 
mediates circadian rhythms and that its effects are exerted through the differential 
activation of estrogen subtype receptor 1 (ESR1) and estrogen subtype receptor 2 
(ESR2).  ESR1 primarily mediates the magnitude of activity, while activation of ESR2 
alters the timing of when this activity occurs.  Specifically, I found that estradiol 
increases total wheel running activity, consolidates activity to the dark phase, and 
increases the amplitude of the activity rhythm through a mechanism dependent on the 
activation of ESR1.  Conversely, an ESR2-dependent mechanism is responsible for 
activational estradiol’s ability to distribute activity across the subjective night, delay the 
acrophase of wheel running activity, reduce the phase angle of activity onset, and dampen 
the behavioral response elicited by a light cue in the early evening.  I also discovered that 
the endogenous length of day is mediated through activation of either ESR1 or ESR2.   
Further, developmental estrogenic signaling during a neonatal critical period 
associated with maturation of the suprachiasmatic nucleus (SCN), the ‘master clock’, 
programs both the quantity of total wheel running activity as well as the distribution of 
this activity across the subjective night.  It also organizes the acrophase and the 
endogenous length of the active period, a measure that was not affected by activational 
estrogenic signaling.  While the effects of activational estradiol were robust and altered 
nearly all examined parameters, modulation of estradiol during the first 5 days of life 
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induces more subtle control over daily and circadian activity variables.  Additionally, 
these effects are often sex specific. 
Finally, I show here that estradiol not only modifies functional circadian 
behavioral outputs, but also acts to regulate the master oscillator itself.  The 
transcriptional milieu within the SCN is substantially altered by estradiol at a time of day 
when estradiol most strongly opposes photic-induced behavioral plasticity.  Estradiol 
primarily exerts these effects through downregulation of message expression.  
Importantly, I show, for the first time, that estradiol significantly dampens the expression 
of transcripts associated with neuronal and synaptic plasticity mechanisms.  Together, the 
studies presented here greatly expand our understanding of estrogenic signaling within 
the SCN and its ability to shape and modify daily and circadian behavioral rhythms 
throughout the lifespan. 
 
